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Abstract !
 
The giant muscle protein titin is a central player in cardiovascular health and 
disease. Titin molecules spanning half of the sarcomere form a filament system in 
striated muscles. The titin filament is not only an essential structural component of 
sarcomere, but also plays a central role in myofibril signaling through its kinase 
domain (TK) and numerous protein ligands. Thus, not surprisingly, mutations in this 
molecule might have detrimental effects. In this work a structure-driven approach was 
taken to re-evaluate titin kinase catalytic activity and the pathogenicity of two 
cardiomyopathy-associated titin mutations. 
 
Comparison of recombinant preparations from E .coli and insect cells revealed 
intrinsic inactivity of TK. It was demonstrated that previously reported 
phosphotransfer activity towards Tcap (a small Z-disc protein) is due to contaminant 
kinase activity from insect cells but not TK itself. Next, it was established that the 
eukaryotic host produces structurally indistinguishable TK from that produced in 
insect cells, albeit inactive towards Tcap, classical kinase substrates or extracts from 
mature or differentiating muscles. Structural analysis identified evolutionary 
conserved residue substitutions converting vertebrate TKs to pseudokinases.  
  
The structural context of dilated cardiomyopathy associated mutation was 
revealed in the crystal structure of TK enclosing neighboring domains A170 and M1. 
The mutation site resides in a conserved helix located in the linker region between TK 
and the binding site of ubiquitin E3 ligase MuRF1. Aspartate to valine substitution 
causes disruption of a conserved hydrogen bond and detachment of the affected helix 
from TK. In the context of the titin filament, this causes dissociation of the binding 
site from TK and increases interdomain flexibility. Structural alterations translate into 
increased MuRF1-mediated degradation of mutant titin fragments through the 
ubiquitin-proteasome pathway. Speculatively, haploinsufficiency of mutant titin could 
be a possible pathomechanism leading to dilated cardiomyopathy associated with the 
mutation under study. 
  
!ii!
 Comprehensive analysis of arrhythmogenic left ventricular cardiomyopathy 
associated titin mutation generated a novel model of pathogenesis. In contrast to 
previous reports, we demonstrate that mutation does not cause affected domain I10 
unfolding, and is structurally compatible. Observed destabilization of the domain was 
attributed to a disrupted hydrogen bond, causing increased flexibility. A crystal 
structure of the affected domain flanked by adjacent domains I9-I11 demonstrated 
that threonine to isoleucine substitution might have detrimental effects on interdomain 
arrangement, resulting in exposure of a hydrophobic patch. Functionally, differential 
localization of mutant protein was observed in transgenic muscles. Speculatively, 
mutation could result in impaired folding of mutant protein and lead to accumulation 
of degradation-resistant aggregates or cause an increased stickiness to thin filaments 
as a novel pathomechanism.   
 
Results presented in this work demonstrate that TK is a catalytically inactive 
pseudokinase acting as a molecular scaffold. It was demonstrated that TK and MuRF1 
signaling modules are structurally interconnected and genetic perturbation of this link 
might lead to dilated cardiomyopathy. In similar fashion, genetic alteration of 
interaction between immunoglobulin domains might cause arrhythmogenic left 
ventricular cardiomyopathy. 
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Chapter 1 
General introduction and aims ""
1.1 Introduction 
 
 
 Diseases of the cardiovascular system are the major cause of death worldwide. 
Understanding the molecular mechanisms that underlie the pathogenesis of 
cardiovascular diseases is essential for the development of effective therapies that can 
reduce the increasing mortality rates and treatment costs. Evidence accumulated over 
the past two decades have identified titin as the major coordinator of striated muscle 
homeostasis, and its dysfunction as an important element in the pathogenesis of 
cardiovascular diseases. At up to 4.2 MDa titin is the largest polypeptide chain so far 
discovered (Bang et al., 2001). Whilst the titin polypeptide is easily overlooked by 
standard analytical procedures, titin is in fact the third most abundant component of 
vertebrate striated muscle after myosin and actin (Fulton and Isaacs, 1991, Labeit et 
al., 1997). Titin molecules from adjacent half-sarcomeres are connected within the Z-
disk and in the M-line lattices by interactions with Z-disc and M-line proteins, making 
a continuous filament system within the myofibril. Titin filaments contribute to the 
muscle homeostasis in two major ways: the maintenance of muscle biomechanical 
properties and the functional integration of sarcomere signaling pathways. Titin 
elasticity plays a crucial role in restoring the sarcomere back to its slack length after a 
stretch or a contraction (Granzier and Labeit, 2004). In cardiac muscle titin 
contributes to the Frank-Starling mechanism (Fukuda and Granzier, 2005, Helmes et 
al., 2003). Biomechanical properties of titin adjust to changing demands in multiple 
ways. These include alternative splicing (Guo et al., 2010), posttranslational 
modifications (Hidalgo et al., 2009) and ligand binding (Zhu et al., 2009), to name but 
a few. Thus indicating that titin-based force generation is a finely tuned process of a 
central importance. Secondly, multiple ligands make titin a major coordinator of 
sarcomere signaling (Granzier et al., 2002) (Figure 1.1) At Z-disc titin interacts with 
numerous structural and regulatory proteins (Linke and Kruger, 2010, Knoll and 
Buyandelger, 2013) Structurally titin is anchored in Z-discs throught interaction with 
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telethonin (Mues et al., 1998, Gregorio et al., 1998), α-actinin (Eilertsen et al., 1997), 
filamins (Labeit et al., 2006), small ankyrin-1 (Kontrogianni-Konstantopoulos and 
Bloch, 2003), obscurin (Bang et al., 2001) and nebulin in skeletal muscle (Witt et al., 
2006). Moreover, these interactions bear a regulatory aspect, as for example, 
telethonin-MLP (Muscle LIM protein) interaction is a basis of mechanical stretch 
sensor machinery (Knoll et al., 2002) and titin interaction with potassium channels  
contributes to a stretch-dependent regulation of potassium flux in cardiac muscle, 
providing a "mechano-electrical feedback" system (Furukawa et al., 2001). In I- and 
A-bands titin interacts with components of thin (Jin, 2000, Linke et al., 2002, 
Trombitas et al., 1997) and thick filaments (Isaacs et al., 1992, Houmeida et al., 1995, 
Freiburg and Gautel, 1996), respectively. In addition, the I-band is one of the 
localization sites for the calcium dependent proteases, calpains (Hayashi et al., 2008, 
Raynaud et al., 2005) and N2A sequence localized is a binding site for a stretch- 
sensing family of muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP 
(Miller et al., 2003). In the M-band a large proportion of interactions are centred on 
the kinase domain. The family of muscle specific RING-finger (MuRF) ubiquitin 
ligases is either bound in close proximity or directly to the kinase domain (Mrosek et 
al., 2007, Centner et al., 2001, Lange et al., 2005). Furthermore M-line located Ig 
domains and their linking regions interact with various protein ligands. The sequence 
between M3 and M4 domains serves a as binding site for FHL-2 protein which links 
titin to metabolic enzymes (Lange et al., 2002); the M4 domain itself mediates 
interaction with myomesin, thus providing an additional link between titin and thick 
filament (Obermann et al., 1997). Interactions with calpain-3 (Sorimachi et al., 1996) 
and obscurin (Fukuzawa et al., 2008) are central to muscle homeostasis, as mutation-
caused impairment of these interactions are shown to be a pathogenetic factor in the 
development of limb-girdle muscular dystrophy type 2A (Ojima et al., 2010) and C-
terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy 
(Carmignac et al., 2007). Taken together, the titin filament is a major coordinator of 
sarcomere signaling. 
 
 3"
Figure 1.1 Titin and titin ligands. Upper panel. Organization of titin (blue) and 
nebulin (red) in sarcomere from skeletal muscle. Lower panel. Titin-domain 
architecture (N2A-isoform of human skeletal muscle) laid out in a half-sarcomere, 
titin ligands, and main avenues of titin-based signaling Note that the thick filament-
associated segment of titin in the A band contains 6 super-repeats each comprising 7 
modular domains and 11 super-repeats each comprising 11 modular domains. 
Ankrd2, ankyrin repeat domain protein-2; Bin1, bridging integrator protein-1; CARP, 
cardiac-ankyrin-repeat-protein; DARP, diabetes-related ankyrin-repeat protein; FHL2, 
four-and-a-half-LIM-domain protein; MDM2, mouse double minute-2 protein; MLP, 
muscle LIM protein; MURFs (1/2), muscle-specific RING finger proteins(-1/-2); 
MyBP-C, myosin-binding protein C; MyHC, myosin heavy chain; Nbr1, neighbour of 
BRCA1 gene-1 (©2010 by American Physiological Society. 
Taken from Linke and Kruger, 2010.
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 Consequently, titin dysfunction is an important element in the pathogenesis of 
cardiovascular diseases. Up to 108 titin mutations were found to be associated with all 
major types of human cardiomyopathies: dilated (DCM), hypertrophic (HCM), 
arrhythmogenic left ventricular (ARVC) and restrictive (RCM) (Table 1.1 and 
Appendix 1).  
 
Table 1.1 List of cardiomyopathy-linked titin mutations. Location of mutation is 
referenced according the corresponding publication. DCM: dilated cardiomyopathy, 
HCM: hypertrophic cardiomyopathy, ARVC: arrhythmogenic right ventricular 
cardiomyopathy, RCM: restrictive cardiomyopathy, *: stop, IVS: intron, del: deletion, 
ins: insertion, fs: frameshift. (© 2013 Maegen A. Ackermann and Aikaterini 
Kontrogianni-Konstantopoulos. Adapted from Ackermann and Kontrogianni-
Konstantopoulos, 2013 published under the CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/55609) ""
Pathology Mutation Localization Effect Reference 
DCM V54M Z-disc ↓ binding to telethonin 
Itoh-Satoh et 
al., 2002 
DCM R743L Z-disc ↓ binding to α-actinin 
Satoh et al., 
1999 
DCM W976R Z-disc Unknown Gerull et al., 2002 
DCM Q4007* I-band Truncation Itoh-satoh et al., 2002 
DCM Q4249* I-band Truncation Herman et al., 2012 
DCM S4417N I-band ↓ binding to FHL2 
Itoh-satoh et 
al., 2002 
DCM G3470D I-band Unknown Liu et al., 2008 
DCM C13771* I-band Truncation Herman et al., 2012 
DCM G16189* A-band Truncation Herman et al., 2012 
DCM W16359* A-band Truncation Herman et al., 2012 
DCM R17295* A-band Truncation Herman et al., 2012 
DCM R17470* A-band Truncation Herman et al., 2012 
DCM E17783* A-band Truncation Herman et al., 2012 
DCM C18789* A-band Truncation Herman et al., 2012 
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DCM R18858* A-band Truncation Herman et al., 2012 
DCM R18985* A-band Truncation Herman et al., 2012 
DCM R19560* A-band Truncation Herman et al., 2012 
DCM R20858* A-band Truncation Herman et al., 2012 
DCM Q25689* A-band Truncation Herman et al., 2012 
DCM W26632* A-band Truncation Herman et al., 2012 
DCM R26949* A-band Truncation Herman et al., 2012 
DCM K27016* A-band Truncation Herman et al., 2012 
DCM W27147* A-band Truncation Herman et al., 2012 
DCM Y27567* A-band Truncation Herman et al., 2012 
DCM W29318* A-band Truncation Herman et al., 2012 
DCM R29415* A-band Truncation Herman et al., 2012 
DCM E29510* A-band Truncation Herman et al., 2012 
DCM Q30081* A-band Truncation Herman et al., 2012 
DCM R31195* A-band Truncation Herman et al., 2012 
DCM K31371* A-band Truncation Herman et al., 2012 
DCM S31841* A-band Truncation Herman et al., 2012 
DCM R32069Q A-band Unknown Matsumoto et al., 2005 
DCM IVS118-g>a I-band Truncation Herman et al., 2012 
DCM IVS172-g>c I-band Truncation Herman et al., 2012 
DCM IVS172+g>a I-band Truncation Herman et al., 2012 
DCM IVS185-2a>g I-band Truncation Herman et al., 2012 
DCM IVS230+g>t A-band Truncation Herman et al., 2012 
DCM IVS237+3a>g A-band Truncation Herman et al., 2012 
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DCM IVS253-5t>a A-band Truncation Herman et al., 2012 
DCM IVS254-g>a A-band Truncation Herman et al., 2012 
DCM IVS255+g>a A-band Truncation Herman et al., 2012 
DCM IVS271+5g>a A-band Truncation Herman et al., 2012 
DCM IVS274-2a>g A-band Truncation Herman et al., 2012 
DCM IVS276+5g>c A-band Truncation Herman et al., 2012 
DCM IVS277+g>a A-band Truncation Herman et al., 2012 
DCM IVS279+2t>a A-band Truncation Herman et al., 2012 
DCM IVS302+g>c A-band Truncation Herman et al., 2012 
DCM 6247 del g R2083fs I-band Unknown 
Herman et al., 
2012 
DCM 19183 del g S6395fs I-band Unknown Herman et al., 2012 
DCM 44336 del a E14779fs A-band Unknown Herman et al., 2012 
DCM 44725 del t D14909fs A-band Unknown Herman et al., 2012 
DCM 45322 del t F15108fs A-band Unknown Herman et al., 2012 
DCM 53935 del c E17978fs A-band Unknown Herman et al., 2012 
DCM 60147 del c P20049fs A-band Unknown Herman et al., 2012 
DCM 64925 del t K21640fs A-band Unknown Herman et al., 2012 
DCM 65867 del a E21956fs A-band Unknown Herman et al., 2012 
DCM 67745 del t P22582fs A-band Unknown Herman et al., 2012 
DCM 81536-81537 del ct S27179fs A-band Unknown 
Herman et al., 
2012 
DCM 84977-84980 del atta Y28326fs A-band Unknown 
Herman et al., 
2012 
DCM 82381 del g A27460 A-band Truncation Gerull et al., 2006 
DCM 89180-89184 del ttaaa T29725fs A-band Unknown 
Herman et al., 
2012 
DCM 91043 del a N30348fs A-band Unknown Herman et al., 2012 
 7"
DCM DCM 93376-93377 del ag  R31126fs A-band Unknown 
Herman et al., 
2012 
DCM 97824-97831 del agtgacca A32606fs M-line Unknown 
Herman et al., 
2012 
DCM 98964 del a K32987fs Ig150 M-line Unknown 
Herman et al., 
2012 
DCM 38621 ins a A12873fs I-band Unknown Herman et al., 2012 
DCM 28kb duplication of ex 72-124 I-band Unknown 
Herman et al., 
2012 
DCM 53145 ins g E17715fs A-band Unknown Herman et al., 2012 
DCM 58880 ins a* S19628fs A-band Truncation Yoskovitz et al., 2012 
DCM 62986-62987 ins at ex. 326 A-band Truncation 
Gerull et al., 
2002 
DCM 72178 ins t Q24059fs A-band Unknown Herman et al., 2012 
DCM 78372 ins a G26124fs A-band Truncation Yoskovitz et al., 2012 
DCM 90493 ins cct T30165fs A-band Unknown Herman et al., 2012 
DCM 91537 ins a T30513fs A-band Unknown Herman et al., 2012 
DCM 
67057-67063 del 
gcatatg ins 
ta^A22353fs 
A-band Unknown Herman et al., 2012 
DCM 72723-72739 del a ins aga S24241fs A-band Unknown 
Herman et al., 
2012 
HCM R740L Z-disc ↑ binding to α-actinin 
Satoh et al., 
1999 
HCM S3753Y I-band ↑ binding to FHL2 
Itoh-Satoh et 
al., 2002 
HCM R8500H I-band ↑ binding to CARP 
Arimura et al., 
2009 
HCM R8604Q I-band ↑ binding to CARP 
Arimura et al., 
2009 
HCM IVS155+g>t I-band Unknown Herman et al., 2012 
HCM 23798-23810 del gtcaagatatctg G7933fs I-band Unknown 
Herman et al., 
2012 
HCM 60147 del C A-band Unknown Herman et al., 2012 
ARVC T2896I I-band ↓ Stability Taylor et al., 2011 
ARVC Y8031C I-band Unknown Taylor et al., 2011 
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ARVC H8848Y I-band Unknown Taylor et al., 2011 
ARVC I16949T A-band Unknown Taylor et al., 2011 
ARVC A18579T A-band Unknown Taylor et al., 2011 
ARVC A19309S A-band Unknown Taylor et al., 2011 
ARVC P30847L A-band Unknown Taylor et al., 2011 
ARVC M33291T M-line Unknown Taylor et al., 2011 
RCM Y7621C I-band Unknown Peled et al., 2014 "
  
 The vast majority of titin mutations have been causally linked to DCM (Itoh-
Satoh et al., 2002, Satoh et al., 1999, Gerull et al., 2006, Gerull et al., 2002, 
Matsumoto et al., 2005, Yoskovitz et al., 2012, Herman et al., 2012). In particular, 
mutation caused titin truncations were shown to be a common cause of dilated 
cardiomyopathy, found in  25% of familial cases of idiopathic dilated cardiomyopathy 
and in 18% of sporadic cases (Herman et al., 2012). However, the pathomechanism 
leading to DCM due to titin truncations might be rather pleotropic in nature as some 
truncated titin variants are found only at transcript level (Gerull et al., 2006), whereas 
others are integrated into the sarcomere (Gerull et al., 2002). Moreover, the unequal 
distribution of truncating mutations in DCM patients might indicate that truncated 
titins are integrated into the sarcomere and cause dilated cardiomyopathy by means of 
a dominant negative mechanism and not haploinsufficiency (Herman et al., 2012). In 
comparison, nonsense mutations have been causally linked to HCM (Satoh et al., 
1999, Satoh et al., 2002, Arimura et al., 2009), ARVC (Taylor et al., 2011) and RCM 
(Peled et al., 2014). Thus, clinical data imply that association of titin mutations with 
cardiomyopathy is a widespread and possibly causative phenomenon. 
  
 However delineating causative genotype-phenotype links in genetic heart 
disorders is a demanding task for the following reasons. Firstly emerging new 
generation sequencing technologies revealed unexpectedly large variation in the 
human genome, consisting mainly of rare genetic variants (Nelson et al., 2012, 
Keinan and Clark, 2012).  Thus, rare sarcomeric gene variations associated with 
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cardiomyopathy in small patient families were found to be present in 17% of the 
NHLBI GO Exome Sequencing Project population (Norton et al., 2012) indicating 
that alone small-size association studies are insufficient to reliably discern disease 
causing mutation from benign rare variants. Secondly, rare genetic variants of 
sarcomeric genes might have very complicated penetrance pattern. It was shown that 
the risk of adverse cardiovascular events grows with increasing numbers of rare 
sarcomeric variants (Bick et al., 2012). Consequently, differentiation between benign 
and pathogenic genetic variants requires integration with functional assays, robust 
bioinformatics, large control cohorts and expert clinical evaluation (Mestroni and 
Taylor, 2013).  
 
 In this work a structure-driven approach was undertaken to gain evidence for 
the discrimination between benign and pathogenic rare titin genetic variations and 
understand the possible molecular pathomechanism.  
 
 A gigantic titin protein is a great challenge for the structural biology.  However, 
due to repetitive nature of the molecule, obtained structures can serve for reliable 
estimations of larger titin fragments. Thus, depth of structural knowledge varies 
among different structural regions of titin (Table 1.2). Out of numerous interactions 
titin is involved in the Z-discs (Hoshijima, 2006) structures are known only for two: 
Z1Z2 with Tcap, a small protein embedding N-termini of the titin into the Z-discs.  
(Pinotsis et al., 2006, Zou et al., 2006) and Z-repeat with α-actinin (Atkinson et al., 
2001). The I-band of titin consists mainly of 50-100 (depending on isoform) Ig-
tandems, however structures of only 8 domains are known to date. This region 
functionally and structurally is divided according to splicing patterns into two 
subregions: the constitutively expressed region is interrupted by alternatively spliced 
Ig-tandems. Functionally it was shown that at least proximal Ig-tandems are not 
extensible upon the physiological sarcomere stretch (Furst et al., 1988) and might 
interact with thin filament (Granzier et al., 1997, Jin, 2000, Trombitas et al., 1997, 
Trombitas and Pollack, 1993, Trombitas et al., 1993). The alternatively spliced elastic 
region of titin is well represented by the I67-I69 tandem. Structure of such a 
comprehensive piece of titin chain revealed high order organization (von Castelmur et 
al., 2008) and allowed generation of a precise model explaining the elasticity of this 
filament region (Lee et al., 2010). Thus, structural knowledge on alternatively spliced 
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regions of titin I-band is sufficient to estimate the mutational effects in this region and 
gain insights into underlying pathomechanisms. However, structural knowledge on 
constitutively expressed regions of titin’s I-band is very scarce. This region is 
represented only by two structures of single Ig domains: I1 from proximal and I91 
from distal regions. Structures of 8 domains from titin’s A-band are known. Analysis 
of titin in the region of A77-A78 revealed conformationally defined interfaces 
possibly leading to local and higher order architecture accommodating molecular 
scaffold functions of this region of titin (Bucher et al., 2010). In similar fashion, 
crystal structure of A168-A170 revealed the molecular determinant for the 
recruitment of the ubiquitin-ligase MuRF1 onto titin (Mrosek et al., 2007). In 
summary, structural knowledge on A-band titin interactions with its ligands: myosin, 
Myosin Binding Protein C and MuRF would advance the understanding of clinical 
relevant A-band mutations associated with hereditary myopathy with early respiratory 
failure (Toro et al., 2013, Ohlsson et al., 2012, Hedberg et al., 2013). The 2200 
residue-long M-line region of titin consists of kinase and 10 Ig domains linked with 
linker sequences of variable length. Structures are known for vast majority of ordered 
domains. Currently structures of only 5 Ig domains are not known. Out of numerous 
interactions formed by the titin M-line region the molecular basis is known only for 
M10 and obscurin-like 1, shedding some light into understanding of tibial muscular 
dystrophy and limb girdle muscular dystrophy 2J (Pernigo et al., 2010). Based on 
structure, a unique TK activation was inferred (Mayans et al., 1998) and structural 
data were used to propose a molecular pathomechanism for how mutation in TK 
causes hereditary myopathy with early respiratory failure (Lange et al., 2005). 
However, this mechanism is under heavy critique, as TK mutation was shown to be a 
benign concomitant genetic variant, whereas pathogenic mutation resides upstream in 
the A-band fibronectin domain (Hedberg et al., 2013, Pfeffer et al., 2013).  Thus, 
some controversy surrounds the underresearched TK region. In particular nothing is 
known about the proposed MuRF1 and TK crosstalk (Centner et al., 2001, McElhinny 
et al., 2002) although the structures of MuRF1 binding site and TK are elucidated. 
Thus structural knowledge on the link between MuRF1 and TK might facilitate 
understanding of their functional crosstalk. 
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Table 1.2 Summary of published titin structures. 
 
 "
Region Structure Residues References 
Z1Z2 
(2A38;2F8V;1YA5) 1-196 
Marino et al., 2006 
Pinotsis et al., 2006, 
Zou et al., 2006 
Z
-disc Z-repeat 
(1H8B) 650-672 Atkinson et al., 2001 
I1 
(1G1C) 2038-2125 Mayans et al., 2001 
I67-I69 
(2RIK; 2RJM) 7211-7490
1 von Castelmur et al., 2008 
I65-I70 
(3B43) 7017-7584* 
von Castelmur et al., 
2008 
I-band 
I91 
(2RQ8;1WAA;1TIT;1TIU) 5253-5341 
Improta et al., 1996, 
Stacklies et al., 2009, 
Yagawa et al., 2010 
A71 
(1BPV) 14859-14961 Goll et al., 1998 
A77-A78 
(3LPW) 15452-15646 Bucher et al., 2010 
A164-A165 
(3LCY) 24032-24225 
Chen et al., no 
publication 
A168-A169 
(2J8H;2J8O;2ILL) 24430-24609 
Muller et al., 2007, 
Mueller-Dieckmann et 
al., 2007 
A
-band 
A168-A170 
(2NZI) 24430-24719 Mrosek et al., 2007 
TK 
(1TKI) 24748-25067 Mayans et al., 1998 
M1 
(2BK8) 25073-25166 
Muller et al., no 
publication 
M4 
(3QP3) 26350-26446 
Sauer et al., no 
publication 
M5 
(1NCT;1NCU;1TNM;1TNN) 26059-26155 
Pfuhl et al., 1997, Pfuhl 
and Pastore, 1995 
M7 
(3PUC) 
26350-26446 
 
Sauer et al., no 
publication 
M
-line 
M10 
(3Q5O;2Y9R;2WP3;2WWK;2WW
M;3KNB) 
26828-26926 
 
Sauer et al., no 
publication; Pernigo et 
al., 2010, Sauer et al., 
2010 
 
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
1 Residue numbering according titin N2A isoform protein NP_596869.4, otherwise according reference 
entry NP_003310 
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1.2 Aims "
 In this work a structure-driven approach was undertaken to gain evidence for 
the discrimination between benign and pathogenic rare titin genetic variations and 
understand the possible molecular pathomechanism. To date no structural data is 
available on the ARVC associated titin T2850I mutation. Therefore it was aimed to 
elucidate structures of wild-type and mutant I10 domain in order to gain insights into 
possible pathomechanism. Moreover, a representative fragment of a constitutively 
expressed Ig-tandem would facilitate the functional understanding of these deviant I-
band regions and form a solid basis for evaluation of future genetic variations. Work 
on M-line region of titin was focused on understanding of possible TK and MuRF 
crosstalk, as a rare genetic variant in this region was found to be associated with 
dilated cardiomyopathy. This complex scientific problem partitioned into two lines of 
work. Firstly, it was aimed to reassess the functionality of TK in order to solve 
controversies surrounding this issue. Secondly, it was intended to gain structural 
knowledge on the physical link between MuRF binding site and TK region to gain 
insights into possible mechanism of functional crosstalk and how mutation in this 
region might disturb it. Taken together, structural knowledge to be gathered in this 
work should specifically shed light on the pathomechanisms of studied disease-
associated variants and would contribute to basic understanding how titin filament 
interconnects signaling pathways and structural components of sarcomere.  
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Chapter 2 
 
Titin kinase is an inactive pseudokinase scaffold 
involved in MuRF1-titin interaction "
2.1 Introduction "
The giant protein titin (3-4.2 MDa according to isoform) is believed to 
orchestrate the response of muscle to mechanical and metabolic stress. Single titin 
molecules span entire half-sarcomeres (from Z-disc to M-lines, >1 µm in length) and 
contain strain compliant elements, forming an elastic lattice within the cytoskeleton of 
acto-myosin motors (Granzier and Labeit, 2005). Titin binds an extensive range of 
myofibrillar proteins, including Tcap/telethonin that have cardio-protective roles 
(Knoll et al., 2011), transcriptional regulators (Lange et al., 2005, Miller et al., 2003), 
and remodeling factors such as calpain proteases (Sorimachi et al., 1996, Ojima et al., 
2010) and E3 ubiquitin ligases (Centner et al., 2001, Mrosek et al., 2007). These 
proteins link titin to the regulation of the membrane potential (Furukawa et al., 2001) 
and to protein turnover and gene expression processes in the sarcomere (Witt et al., 
2008). Taken together, the elastic character of the titin chain and its multiple 
scaffolding interactions make it an optimal platform to integrate force sensing in the 
muscle cell (Granzier and Labeit, 2005).  
 
 The kinase domain near the C-terminus of titin (titin kinase; TK2) in the 
sarcomeric M-line plays an important role in mechanotransduction. TK binds a 
protein complex formed by the autophagosomal receptors nbr1, p62, and the E3 
ubiquitin ligase MuRF2 that regulates protein degradation (Lange et al., 2005, Witt et 
al., 2008). A force-dependent regulation of this signalosome was revealed by the 
beating arrest of cardiomyocytes under hyperkalemic depolarization (Lange et al., 
2005). The arrest induced the disassembly of the TK signalosome and the subsequent """"""""""""""""""""""""""""""""""""""""""""""""""""""""
2 If not indicated otherwise, TK in this work refers to catalytic kinase domain with C-terminal 
regulatory tail.  
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translocation of MuRF2 to the cell nucleus, where it blocked the anabolic action of 
the serum response transcription factor (SRF). Nbr1 and p62 are in vitro substrates of 
TK (Lange et al., 2005), but it is unknown how their phosphorylation regulates the 
function of the signalosome. Intriguingly, a docking site for the ubiquitin ligase 
MuRF1 (a close homolog of MuRF2) has been mapped to a locus of titin immediately 
N-terminal to TK (Centner et al., 2001, Mrosek et al., 2007). MuRF1 is strongly 
upregulated by atrophic stimuli such as immobilization, denervation, nutritional 
deprivation, aging and in disease (e.g. cancer, sepsis and renal failure), being an 
important mediator of muscle wasting (Bodine et al., 2001, Mayans and Labeit, 
2012). The exact signaling relationship of TK, MuRF2 and the vicinal MuRF1 
remains unclear. However, the importance of TK for muscle physiology is 
demonstrated by the severe phenotypes resulting from its genetic defect. Both 
transgenic mouse models (Peng et al., 2005, Peng et al., 2007, Weinert et al., 2006) 
and human patients that express titins with TK deletions (Herman et al., 2012) or 
point mutations (Lange et al., 2005) display life-threatening myopathies. This might 
also reflect additional roles of TK in the myofibril, such as regulation of 
myofibrillogenesis that is exerted through phosphorylation of Tcap, a small protein of 
the Z-disc, initially identified as a TK substrate in differentiating myotubes (Mayans 
et al., 1998).  
 
 All proposed roles of TK in cell signaling assume a kinase activity, where 
phospho-transfer occurs in a stretch-regulated fashion. The crystal structure of TK 
(Mayans et al., 1998) showed that this kinase is inhibited by a C-terminal regulatory 
tail (CRD) that folds against the catalytic core, binding deeply into the ATP binding 
pocket and blocking it (Figure 2.1). In addition, the catalytic aspartate at the active 
site is blocked by an interaction with a tyrosine residue, Y170, from the P+1 loop. For 
TK activation, the steric blockage imposed by both Y170 and CRD need to be 
removed. Early studies (Mayans et al., 1998) indicated that Y170 inhibition is 
released by phosphorylation by a developmentally regulated kinase, but the latter has 
remained unidentified. More uncertain is the mechanism of CRD removal as 
biochemical activators that can displace this tail are yet to be found. However, based 
on atomic force microscopy data and molecular dynamics simulations, a 
mechanoactivation hypothesis has been proposed (Puchner et al., 2008, Grater et al., 
2005, Puchner and Gaub, 2010, Stahl et al., 2011). This hypothesis postulates that 
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cytoskeletal stretch during myofibril function causes the CRD to unwind from the 
catalytic core, freeing TK to adopt a catalytically active conformation. This 
mechanosensory mechanism agrees with the proposed involvement of TK in stretch-
activated pathways in muscle (Lange et al., 2005). For future progress in 
understanding TK function, the interplay between its scaffolding, catalytic and 
mechanosensory processes must be resolved.  
 
 
Figure 2.1 Overall fold representation of TK 
The catalytic kinase core is shown in blue with an accompanying surface 
representation. The C-terminal regulatory domain (CRD) is colored yellow and three 
major components: α-helix 1 (αR1), α-helix 2 (αR2) and β-stand 1 (βR1) are 
indicated. Note that αR2 helix binds deeply into the ATP binding cavity. The lysine 
residue central to ATP binding and catalysis (K36), the catalytic aspartate residue 
(D127) and the inhibitory tyrosine from the P+1 loop (Y170) are displayed. 
 
 
 
 
 Here, we set out to profile the catalytic properties of TK making use of Tcap, its 
most established substrate. Unexpectedly, our structural and catalytic approaches have 
revealed that TK is an inactive pseudokinase. This result points to a new direction in 
understanding the role of TK in muscle signaling, where scaffolding and not kinase 
activity is to take centre stage. "
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"
2.2 Materials and Methods 
 
2.2.1 Cloning "
TK (residues 32172-32492; UniProtKB Q8WZ42) and its variants (TKK36A, 
TKK36L, TKY170E, TKΔR2/Y170E) were cloned into the pET-Trx1a (former pETM-30) 
vector (EMBL collection) using NcoI and Acc65I restriction sites.. This vector fuses a 
His6-tagged thioredoxin and a TEV (tobacco etch virus) protease cleavage site N-
terminally to the target construct. For expression in Sf21 cells, the full-length protein 
encoded by the pET-Trx1a vector (Bogomolovas et al., 2009), including the N-
terminal fusion, was cloned into pFastBac ET vector (EMBL). The NcoI compatible 
PscI site was introduced at the 5’-end of the construct and cloned into a linearized 
vector digested with NcoI/Acc65I restriction enzymes. The variant TKΔR2/Y170E was 
constructed by replacing residues 291-309 forming the regulatory a-helix R2 with the 
sequence GGSGGSA using TKY170E as a template. To ease structural annotation, 
residue 32172 is taken here as residue 1. 
 
TwcK (twitchin kinase) (residues 6251-6537; UniProtKB Q23551) and its 
variants as well as full-length human Tcap (UniProtKB O15273) were cloned into the 
pETM-11 vector that adds a His6-tag and a TEV protease cleavage site prior to the 
inserted protein. For compatibility with TK, residue 6251 in TwcK is considered here 
as 1 (based on the structural alignment in Figure 2.8c). GST tagged titin A168-170 
(residues 31854- 32155), A168-TK (residues 31854-32492), TK and TKY170E were 
cloned into pETM-30 vector (EMBL collection). Mutations were introduced using 
overlap extension polymerase chain reaction. All constructs were verified by 
sequencing. 
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2.2.2 Recombinant protein production  "
Kinase samples were expressed in E.coli SoluBL21 (Genlantis) in TB medium 
supplemented with 50 mg/ml kanamycin. Cultures were grown at 37 °C to an OD600 = 
1. Upon cooling to 16 ˚C, expression was induced with 0.2 mM IPTG and growth 
continued for further 18 hrs. Cells were harvested by centrifugation. The pellet was 
resuspended in lysis buffer (20 mM HEPES pH 8, 250 mM NaCl, 5 mM imidazole, 
0.2% NP40, 2 mM β-ME, 2 mM PMSF), supplemented with DNAse I, lysozyme and 
1 mM PMSF, and lysed by sonification. The supernatant was applied to a Ni2+-NTA 
column (Qiagen) pre-equilibrated in lysis buffer and proteins eluted with 300 mM 
imidazole in lysis buffer without detergent. Tag removal was by incubation with TEV 
protease in 25 mM Tris pH 8, 50 mM NaCl, 5 mM DTT, overnight at RT. Proteins 
were further purified using ion exchange chromatography (HiTrap SP for TK; HiTrap 
Q for TwcK) and gel filtration on a Sephadex S75 16/60 column (GE Healthcare). 
Samples were stored at 4 oC until further use. 
 
Tcap was produced as TwcK but without tag removal or gel filtration. GST-
tagged proteins were purified using Glutathione-Sepharose (GE lifesciences) resin. 
 
For eukaryotic TK expression (Protein Expression and Purification Facility of 
EMBL), Sf21 cells were transfected with the bacmid DNA construct of TK or its 
variants according to manufacturer instructions (Invitrogen Bac-to-Bac system). 
Transfected cells were incubated for 3 days at 27 °C and the supernatant, containing 
recombinant virus, was collected. Amplified virus (10 ml) was added to 1 × 106 Sf21 
cells and incubated at 27 °C for 3 days. Sf21 cells were harvested 72 hrs postinfection 
and stored at -20 oC until protein purification, which followed the procedure above. 
 
2.2.3 Protein stability measurement "
Energy changes (ΔΔG) for the replacement of lysine K36 in the ATP-binding 
pocket with each possible amino acid type were estimated using FoldX (Van Durme 
et al., 2011). Experimental protein stability for selected mutated variants was 
estimated from differences in their melting temperature (Tm) monitored by 
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Differential Scanning Fluorimetry (DFS). DFS measurements were performed using a 
Mx3005p RT-PCR machine (Stratagene). Purified TK, TKK36A and TKK36L samples 
were assayed in 25 µl buffer consisting of 10 mM HEPES pH 7.5, 150 mM NaCl in 
96-well plates. SYPRO-Orange (Invitrogen) was added at a dilution 1:1000. 
Fluorescence was monitored (λex = 465 nm, λem=590 nm) from 25 °C to 85 °C at 1 
°C/min increment. Each measurement was done in triplicate and Tm values 
determined using a modified Boltzmann equation with linear correction of baseline 
drifts (Matulis et al., 2005). 
 
2.2.4 Crystal structure determination "
As previously (Mayans et al., 1998, Mayans and Wilmanns, 1999), crystals 
were grown at 21 °C by the hanging-drop method in 24-well VDX plates (Hampton 
Research). Drops contained 1 µl protein solution (12 mg/ml) and 1 µl reservoir 
consisting of 1.6 M Na/K tartrate, 25 mM sodium acetate pH 4.9, 25 mM imidazole 
pH 7.5, 2.5% PEG 400. Crystal optimization used seeding into solutions with 1.2 M 
Na/K tartrate but of otherwise identical composition. For data collection, crystals 
were flash frozen in liquid nitrogen using mother liquor supplemented with 30% [v/v] 
glycerol. X ray diffraction data were collected at 100 K on beamline I04, DIAMOND 
(Didcot), at a λ = 0.9763 Å on a ADSC Quantum detector. The data were processed 
with XDS/XSCALE (Kabsch, 2010) (Table 2.1). As before, crystals contained two 
molecular copies in the asymmetric unit (rmsd=0.14 Å, in MUSTANG (Konagurthu 
et al., 2006)). Phasing was by molecular replacement in Phaser (McCoy et al., 2007) 
using one copy of eukaryotic TK (PDB entry 1TKI) as a search model. Model 
refinement and solvent building was in PHENIX (Adams et al., 2011), applying 
simulated annealing with a starting temperature of 5000 °C. Manual building was in 
COOT (Emsley et al., 2010). Coordinates and structure factors have been deposited 
with the PDB (entry 4JNW). 
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2.2.5 In vitro phosphorylation assays "
Phosphorylation assays were performed in 20 µl assay buffer (20 mM Tris-
HCl pH 7.4, 10 mM magnesium acetate, 0.05% NP40, 0.1 mM DTT, 0.2 mg/ml 
acetylated BSA) containing 0.4 mM ATP (0.2 µCi/reaction of [γ-33P]ATP) at 30 °C. 
Tcap, MLC-derived peptide (KKRARAATSNVFS), Tcap-derived peptide 
(RRSLSRSMSQEAQRG), casein and myelin basic protein were tested at 4 
µg/reaction. Where indicated, the reaction mixture was supplemented with 0.5 mM 
CaCl2 and 0.4 µg/reaction calmodulin from bovine testis (Sigma-Aldrich). For 
reaction mixtures that assayed peptide substrates, an aliquot was withdrawn at 
indicated time points and spotted on EDTA impregnated P81 phosphocellulose paper 
(Whatman). The latter was washed extensively with 75 mM orthophosphoric acid and 
once with ethanol, dried and exposed to a phosphoscreen. Reaction mixtures with 
protein substrates were first separated on SDS-PAGE, the gel briefly stained, dried 
and exposed to the phosphoimager screen. Screens were imaged with a Fujifilm BAS 
2500 phosphoimager and images processed using AIDA (Raytest). "
2.2.6 Preparation of inactivated C2C12 extracts "
C2C12 cells were grown on gelatin coated plastic flasks in DMEM, 10% fetal 
calf serum, 1x ITS, penicillin, streptomycin. For differentiation, the medium was 
changed to DMEM, supplemented with 2% horse serum and penicillin/streptomycin 
once the cells reached 70-90% confluence. For FSBA extract inactivation, cells were 
lysed in 50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40. Clarified lysate was depleted 
of endogenous ATP on a desalting column (GE Lifesciences) and treated with 20 mM 
FSBA at 30 °C for 1 hr. FSBA was removed by buffer exchange into phosphorylation 
assays buffer (above) supplemented with 5 mM DTT.  
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2.2.7 Pull-downs using recombinant titin fragments on muscle 
extracts 
!
Quadriceps tissue from adult mice was pulverised under liquid nitrogen and 
the powder homogenized in 20 mM Tris pH7.5, 100 mM NaCl, 2 mM b-ME and 
Complete Protease Inhibitor (Roche). Extraction proceeded for 90 min on ice. The 
resulting extracts were clarified at 3000g for 30 min, aliquoted, frozen in liquid 
nitrogen and stored at -80 °C.  
 
For GST pull-downs, 50 µg each of GST, GST-A168-170, GST-A168-TK, 
GST-TK and GST-TKY170E, were immobilized on 30 µl of Glutathione-Sepharose-
beads and washed with PBS, 0.1% NP40. Extracts were thawed on ice and spun for 1 
min at 21000xg. The supernatant was diluted by adding 3 volumes of PBS, 0.1% 
NP40. Next, 1 ml of diluted extract was mixed with 30 µl of beads loaded with a 
given titin-fragment and incubated for 16 hrs at 4°C under light stirring. Mixtures 
were spun for 1 min at 1000g, supernatants were removed and the beads washed 3x 
with 1 ml PBS, 0.1% NP40. After a final wash with PBS, supernatants were removed 
and the beads resuspended in SDS sample buffer. Bound material was examined by 
SDS-PAGE and Western-blotting using a MuRF1 specific antibody. 
 
2.2.8 Filter Binding Assay 
!
Purified His6-MuRF1-coiled coil (aa169-263, Q969Q1; reported in Mrosek et 
al.) was biotinylated with NHS-PEG4-Biotin (Thermo Scientific). To remove 
unreacted biotin, the sample was filtered twice through a PD-10 column (GE 
Healthcare) in PBS. 1 mM DTT and 50% glycerol were added and the sample frozen 
until further use. 
 
Purified titin constructs were spotted (approx. 1 µg) on nitrocellulose 
membranes pre-wetted with TBS (25 mM Tris pH 7.5, 150 mM NaCl). The filter was 
blocked by TBST/5% milk, washed with TBST (TBS + 0,05% Tween 20) and 
incubated for 3 hrs with biotinylated MuRF1 coiled-coil at a concentration of 0.5 
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µg/ml in TBST/1%milk. The membrane was washed in TBST and incubated for 1 hr 
in TBST containing 2 µg/ml streptavidin conjugated to alkaline phosphatase (Thermo 
Scientific). After washes in TBST and a final wash in TBS, the detection with 
NBT/BCIP was done as described by the supplier (Roche). ""
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2.3 Results "
2.3.1 Preparations from insect cells contain a contaminant Tcap 
phosphorylating activity  "
We tested the activity of TK samples (comprising the catalytic kinase core and 
CRD) on the Tcap substrate by expressing three TK variants in Sf21 insect cells: 
wild-type TK, the activated phosphomimic TKY170E, and the constitutively inactive 
TKK36L (mutated residues illustrated in Figure 2.1). In TKY170E, the mutation removed 
the inhibition of the catalytic aspartate by the tyrosine residue in the P+1 loop. This 
sample has been previously reported to be active (Mayans et al., 1998, Zou et al., 
2003) In TKK36L, the highly conserved lysine residue involved in the coordination and 
processing of ATP was mutated into an unreactive leucine group that abolishes 
catalysis. Mutation of this lysine residue into e.g. alanine, histidine, methionine or 
isoleucine is an established method to generate inactive kinases (Gloeckner et al., 
2006, Iyer et al., 2005, Ling et al., 1999, Shaw et al., 2004). Although mutation to 
alanine is most common, in TK this exchange resulted in certain structural instability. 
Using FoldX (Van Durme et al., 2011) and Differential Scanning Fluorimetry to 
measure sample melting curves, we identified leucine to be well tolerated by the TK 
fold (Figure 2.2). Thus, TKK36L was used throughout this work. 
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Figure 2.2 Stability of TK lysine mutants 
a. Energy changes (ΔΔG) for the replacement of lysine K36 by every other amino 
acid calculated using FoldX. The values confirm observations that the conventional 
replacement of K36 to alanine is poorly tolerated leading to the destabilization of the 
N-terminal lobe of the TK fold. A replacement of this residue by leucine, however, is 
predicted to agree well with the structure of TK; b. DSF denaturation traces recorded 
at λem=590 nm. Substitution of K36 for alanine (TKK36A) had a clear destabilizing 
effect (DTm= 6.6 °C) on TK, whereas the stability of TKK36L (DTm= 2.2 °C) was 
approximately equivalent to that of wild-type TK. 
 
 
 
In activity assays that used ATP[γ-33P], all three TK variants – including the 
inactive TKK36L – showed similar phospho-transfer activities on Tcap and were 
modestly stimulated by Ca2+/calmodulin (Figure 2.4a). As an independent validation, 
we studied the activity of immuno-complexed wt-TK where its active site had been 
blocked by a specific antibody directed against the P+1 loop (the efficient 
complexation of TK by this antibody is shown in Figure 2.3).  
 
Figure 2.3 Dot blot assays of anti-TK and anti-MuRF1 antibodies. anti-MuRF1 
antibodies (a) recognize the spotted MuRF1 sample, but not the TK constructs, 
whereas anti-TK antibodies recognize TK, but not MuRF1 or titin Ig/Fn3 domains 
(titin sample). Antibodies were produced against the synthetic P+1 loop peptide (TK) 
or the recombinant protein (MuRF1) in rabbits and purified using the immobilized 
antigens. "
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Immuno-complexed TK, non-complexed TK samples, and non-treated TK 
controls showed similar levels of activity (Figure 2.4b). Hence, both activity data 
from mutated and immuno-complexed TK samples suggested that the insect cell 
preparations catalyzed Tcap phosphorylation in a TK-independent way, with kinase 
activity arising from other component(s) in the cell milieu.  
 
 
Figure 2.4 Tcap phosphorylation assays using TK preparations from insect cells  
a. Preparations of wild-type TK, the activated TKY170E phosphomimic and the 
constitutively inactive TKK36L phosphorylate Tcap comparably and stimulated by 
Ca2+/calmodulin. SDS-PAGE (left) and autoradiogram (right) are shown; b. 
Phosphorylation assay of TK sterically inhibited by immuno-complexation with an 
antibody raised against the P+1 loop vicinal to the active site. An antibody (anti-
MuRF1) that does not complex TK is included for comparison; c. Untransfected Sf21 
cell extracts supplemented with Tcap (but not Ca2+/calmodulin) display 
phosphorylating activity (the stimulation of catalysis upon addition of calmodulin was 
~25%, this modest activation is likely due to the presence of endogenous calmodulin 
in the extract). SDS-PAGE (left) and autoradiogram (right) revealing Tcap 
phosphorylation; d. Segregation of phosphorylating activity (cyan) and TK presence 
(red) during purification. Sf21 cell crude extract containing the recombinant TKK36L 
was filtered through a Ni2+NTA column. Bound proteins were eluted with a linear 
gradient of imidazole (100% buffer B=0.3 M imidazole; green line) and monitored by 
A280; the resultant chromatogram is in blue. The content of TKK36L in eluted fractions 
was determined by spot-blot immunoassay using anti TK P+1 loop antibody. The 
amount of colored product quantified densitometrically was proportional to the 
amount of TKK36L in each fraction (red). Phosphorylation of a Tcap-derived peptide 
substrate in the presence of calmodulin was quantified in each fraction 
densitometrically by standard phosphorylation assay that used [γ-33P]ATP and 
spotting on P81 paper (cyan). The data show that Tcap phosphorylation segregated 
from TKK36L.  
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Further evidence that the observed catalysis resulted from a contaminant 
kinase was derived from TK purification. Recombinant TK segregated from the Tcap 
phosphorylating activity during fractionation (Figure 2.4d) and phospho-transfer 
activity on Tcap decreased progressively as TK purity increased. The resulting highly 
pure TK samples showed 80-fold less activity than initial preparations (Figure 2.5). 
The existence of such contaminating kinase activity was finally confirmed by 
assaying non-transfected Sf21 cell extracts, which displayed notable phosphorylation 
of Tcap (Figure 2.4c). Efforts to identify the contaminant kinase during this work 
were not successful. Although a protein candidate could be isolated (Figure 2.5), 
Sf21 cells originate from Spodoptera frugiperda whose genome is not sequenced, 
impeding the identification of proteins through proteomic methods. In brief, these 
data show that Tcap is a substrate of endogenous kinases in Sf21 cells.  
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Fig 2.5 Phospho-transfer activity does not segregate with TK in purification 
In vitro Tcap phosphorylation assays using a. partially purified TK samples after one-
step affinity chromatography and b. TK samples thoroughly purified using the three-
step chromatography protocol described in Methods. Both a. and b. show: Coomassie 
stained SDS-PAGE of reaction mixture (left), autoradiogram of phosphorylated 
samples (center) and SDS-PAGE of the TK sample prior to being added to the 
reaction mixture (right). A same amount of total protein content (as estimated using 
A280) was used in both experiments; c. Densitogram showing a quantification of Tcap 
phosphorylation according to autoradiograms. The quantitation shows that purified 
TK samples displayed 80-fold less phosphor-transfer activity than partially pure TK 
samples. A contaminant (red pointer) co-purifies with TK at low levels. We speculate 
that this is the likely kinase acting on Tcap. Efforts to identify this protein through 
proteomic approaches were not successful as the genome of Spodoptera frugiperda is 
not available. 
 
"""
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2.3.2 TK produced in E.coli is catalytically inactive """ Since kinases present in insect cells preparations masked the potential 
catalysis of TK on Tcap, we established the over-production of TK in E. coli. To 
validate that the bacterial form of this sample was viable, we performed a mass 
spectrometry analysis of TK samples from E. coli and Sf21 cells. The data confirmed 
that neither of the proteins was truncated or otherwise chemically compromised (e.g. 
ΔMM from full mass theoretical values of TKY170E from Sf21 and E.coli cells was 
+0.7 Da and +1.8 Da, respectively). The bacterially expressed TK had no phospho-
transfer activity on Tcap or on the universal kinase substrates myelin basic protein 
and casein. This agrees with previous observations of inactivity of bacterial TK 
(Puchner et al., 2008). To test whether the lack of catalysis resulted from fold defects 
in the bacterial sample, we elucidated its crystal structure to 2.06 Å resolution (Table 
2.1). Noteworthy, crystals of eukaryotically expressed TK belonged to space group 
P212121 with cell dimensions 78.61 Å, 89.77 Å, 113.32 Å and diffracted to 2.0 Å 
resolution (Mayans et al., 1998, Mayans and Wilmanns, 1999). That lattice and the 
one of bacterially-expressed TK in this study are identical.   
 
 Crystallization used previous protocols for Sf9-expressed TK (Mayans and 
Willmans, 1999) and crystals reproduced the lattice parameters of the latter (Mayans 
et al., 1998). Following bias removal by simulated annealing, the resulting model of 
bacterially-produced TK was in complete agreement with that of Sf9-expressed 
samples (rmsd=0.29 Å for all Cα atoms, calculated with MUSTANG; Konagurthu et 
al., 2006) (Figure 2.6a). These data confirmed that there are no noticeable molecular 
differences between bacterial and eukaryotic forms of TK and that the absence of 
catalysis on Tcap signifies that Tcap is not a substrate of TK.  
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Figure 2.6 Structural and functional characterization of TK produced in E.coli 
a. Superimposition of the crystal structures of TK expressed in bacteria (red) and 
insect cells (PDB entry 1TKI) (blue). The overall RMSD for Ca atoms is 0.29 Å; b. 
Representation of the activated variant TKΔR2/Y170E, where the deleted fraction is in 
grey and the added loop is shown schematically in red. The sequence exchanges in 
this variant are shown below; c. Identification of potential TK substrates in 
differentiating C2C12 cell extracts depleted of endogenous kinases by treatment with 
FSBA. Protein kinase A (PKA) was used as positive control. Autoradiogram (panel c) 
and densitogram of phospho-image (lower panel) are provided. The data show no 
significant differences in labeling pattern when comparing cell extract alone or 
supplemented with activated forms of TK. 
 
 
  
  
 We then examined whether muscle cell extracts contain substrates for the 
bacterially expressed and highly purified TK preparations by performing 
phosphorylation assays using wt-TK and TKY170E on extracts from differentiating 
murine C2C12 myocytes (day 2) as well as gastrocnemius muscle from adult mouse 
(the extracts were depleted from endogenous kinase activities using FSBA). This 
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work did not reveal candidate TK substrates (Figure 2.6c). To test whether this result 
reflected tight TK auto-inhibition, we designed the variant TKΔR2/Y170E, where the 
inhibition of the ATP-binding pocket by the regulatory βα-helix R2 of the CRD had 
been removed (nomenclature as in Figure 2.1). In TKΔR2/Y170E, helix R2 was 
substituted by a flexible loop that links helix R1 to the C-terminal b-strand R3 
(Figure 2.6b). As before, assaying this dually activated variant did not reveal any 
candidate substrates in cell extracts (Figure 2.6c). These results suggest that inactivity 
is a genuine characteristic of TK. 
Table 2.1  Data collection and refinement statistics 
 TK 
Data collection  
Space group P212121 
Cell dimensions    
    a, b, c (Å) 78.86, 89.73, 113.88 
Resolution (Å) 28.9-2.06 (2.1-2.06) 
No. reflections 49667 (2681) 
Rsym(I) (%) 9.1 (56.2) 
I / σI 13.9 (3.6) 
Completeness (%) 97.9 (95.4) 
Redundancy 5.7 (5.3) 
  
Refinement  
Resolution (Å) 28.98-2.06 
Rwork / Rfree (%)b 16.63 / 20.37 
No. atoms  
    Protein 5235 
    Ligand/ion 28 
    Water 469 
B-factors (A2)  
    Protein 22.8 
    Ligand/ion 48.4 
    Water 30.7 
R.m.s. deviations  """"Bond"lengths"(Å)" 0.007"""""Bond"angles"(°)" 1.000"
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2.3.3 TK contains atypical residues in its catalytic motifs "
To explore the molecular basis of the apparent inactivity of TK, we examined 
the sequence composition of its active site. A multiple sequence alignment of TK 
sequences (Appendix 2) revealed consistent deviations from canonical active motifs: 
namely, the bulky hydrophobic residue methionine in position 2 of the VAIK motif 
and a glutamate in the DFG motif. The canonical VAIK motif (Boudeau et al., 2006, 
Endicott et al., 2012) is located in strand-β3 and contains the catalytic lysine that ion-
pairs the non-transferable α- and β-phosphates of ATP. There is a strong selection for 
small hydrophobic residues, such as alanine or valine, in position 2 of the VAIK 
sequence. This residue forms the bottom of the cavity that accommodates the purine 
heterocycle moiety of ATP. A bulky residue at this position, as methionine in TK, 
might sterically hinder ATP binding or lead to a non-catalytically viable binding 
mode. The latter case appears likely as AFM studies of TK unfolding in the presence 
of ATP suggest that binding occurs (Grater et al., 2005, Puchner et al., 2008). This 
deduction also agrees with studies on B-Raf where substitution of that residue with 
methionine did not abolish ATP binding (Taylor et al., 2013), and with findings on 
JAK2, which has a leucine residue in this position and binds ATP in an 
unconventional way (Bandaranayake et al., 2012). Interestingly, in those rare cases 
where TK sequences deviate from the methionine residue at this position, they always 
contain leucine instead, supporting the view of a deviant ATP binding mode (see 
Appendix 2). In the DFG motif, aspartate chelates the magnesium ion that 
coordinates the β- and γ-phosphates of ATP. This residue is conserved across most 
members of the protein kinase-like superfamily (Scheeff and Bourne, 2005). 
Although glutamate and aspartate are chemically similar, this substitution is sufficient 
to inactivate phospho-transfer in kinases (Brown et al., 1995, Schu et al., 1993). In the 
human kinome (Scheeff et al., 2009), the deviant residues found in TK are extremely 
rare among active kinases (Figure 2.7). TK is the only known human kinase that 
contains glutamate instead of aspartate in the DFG motif, while ATR kinase is the 
only other human kinase containing a methionine in position 2 of the VAIK motif, 
although its level of activity is unclear. In contrast, among pseudokinases there is no 
marked selection for given residues in position 2 of the VAIK motif or aspartate in the 
DFG signature. Thus, the YMAK/EFG signatures clearly point to irregular catalytic 
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properties in TK. 
Figure 2.7 TK contains atypical residues in catalytic motifs.  
a. Distribution of residues in position 2 of the VAIK motif and position 1 of the DFG 
motif in protein kinases of the human kinome. The classification of kinases and 
pseudokinases was taken from (Scheeff et al., 2009). TK, the only human kinase 
containing an EFG motif, is misclassified as an active kinase due to previous reports 
of catalysis on Tcap (Mayans et al., 1998, Zou et al., 2003, Lange et al., 2005). Other 
kinases with deviant catalytic motifs are: CASK (GFG motif); ATR (xMxK motif); 
LMR2, NEK8 and RIPK1 (IxK); DNAPK, FRAP and SMG1 (LxK); b. Commonly 
occurring residues in the VAIK and DFG motifs of titin kinases from vertebrate 
(upper) and invertebrate titin-like kinases (lower). Sequences for representative 
kinases of each group are given in Appendix 2.   
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Interestingly, an exploration of sequences of TK-like kinases from 
invertebrates that included twitchin and TTN-1 kinases from nematodes and mollusks, 
and projectin from insects showed that these homologs contain canonical catalytic 
motifs characteristic of active kinases (Appendix 2). In agreement, the twitchin 
kinases from Aplysia and C. elegans exhibit high levels of catalysis (Heierhorst et al., 
1996, Lei et al., 1994, von Castelmur et al., 2012). This suggests an evolutionary 
dichotomy where invertebrate members of the TK family are functional enzymes, but 
the vertebrate counterparts are inactive pseudokinases.  "
2.3.4 Transfer of YMAK/EFG TK signature motifs to twitchin kinase 
abolishes catalysis "
To study the role of the atypical, conserved methionine and glutamate residues 
in the active site of TK, we introduced these residues into twitchin kinase from C. 
elegans (ceTwcK). The latter is a close homolog of human TK that is well 
characterized structurally and biochemically (Heierhorst et al., 1996, Lei et al., 1994, 
von Castelmur et al., 2012). ceTwcK (bacterially expressed) exhibits elevated levels 
of catalysis when assayed on a model peptide substrate derived from myosin light 
chain (MLC) protein. ceTwcK and TK share high conservation (34% sequence 
identity; Figure 2.8c) and structural similarity (rmsd for Cα atoms = 1.29 Å when 
comparing the structure of TK in this work and PDB entry 3UTO using MUSTANG, 
Konagurthu et al., 2006) (Figure 2.8a). The active sites of these two kinases are in 
close structural agreement, particularly their ATP binding pockets, their β3 strands 
and the D/EFG motifs (Figure 2.8b). Thus, we concluded that ceTwcK is a suitable 
template to investigate the effect of the unusual motifs of TK on catalysis.  
 
 Based on this proviso, the mutations A34M and/or D147E were introduced in 
ceTwcK (variants ceTwcKA34M, ceTwcKD147E, ceTwcKA34M/D147E) and 
phosphorylation assays carried out on the MLC-derived peptide substrate. The double 
mutant ceTwcKA34M/D147E was generated to account for the possible compensatory co-
evolution of these substitutions in TK. In contrast to wild-type ceTwcK, that showed 
its characteristically high activity, all generated mutants lacked measurable phospho-
transfer catalysis (Figure 2.8d). To confirm that this result was not due to 
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unsuspected distortions of the active site of ceTwcK caused by the mutations, we 
generated the variant ceTwcKA34V as positive control. In this construct, the alanine in 
the VAIK motif is replaced by a valine residue, which is found in the catalytically 
active TwcKs from mollusks (Appendix 2) as well as 5% of the active members of 
the human kinome (Scheeff et al., 2009) As expected, ceTwcKA34V retained 
noticeable levels of catalysis (Figure 2.8e). These results indicate that the two 
atypical active site residues M34 and E147 in TK are sufficient to inactive it into a 
pseudokinase state. "
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Figure 2.8 Comparison of TK and TwcK active sites.  
a. Structural superimposition of TK and ceTwcK (PDB entry 3UTO). Ribbon 
thickness and coloring correlate with the rmsd values of the superimposition as given 
in the accompanying scale (minimum, maximum and average values are shown). The 
structural agreement is excellent overall including active site regions, divergences 
only occur in peripheral loop areas; b. Detailed comparison of the ATP binding 
pockets of TK (green) and ceTwcK (pink) (numbering corresponds to TK). Boxed 
labels indicate TK residues that were trans-engineered into ceTwcK; c. Structure-
based sequence alignment of human TK and ceTwcK corresponding to the 
superimposition displayed in a. and b. The canonical composition of functional motifs 
is shown in red, the P+1 loop is boxed and the tyrosine residue undergoing 
phosphorylation in TK is indicated with an asterisk; d. Comparative autoradiogram of 
catalysis by ceTwck and its variants TwcKA34M, TwcKD147E and TwcKA34M/D147E 
carrying TK residues in their ATP binding pockets. The time course shows 
phosphorylation of a MLC-derived peptide; e. Comparative autoradiogram of the 
catalysis from ceTwck and TwcKA34V. The latter carries the non-inactivating valine 
residue commonly found in the ATP binding pocket of TwcK from molluscs ""
""
""
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2.3.5 TK supports the interaction of M-line titin with the atrogin 
MuRF1 "
Based on these findings, we reassessed how TK might contribute to muscle 
signaling in non-catalytic ways. The binding of the muscle-specific E3 ubiquitin 
ligase MuRF1 in the immediate vicinity of TK is well documented (Centner et al., 
2001, Mrosek et al., 2007). MuRF1 binds a tandem of Ig-Ig-Fn domains, A168-A170, 
immediately preceding the TK domain. The binding is mediated by the C-terminal 
helical domain of MuRF1 and determined by the presence of a loop with sequence 
KTLE in the titin domain A168 (Mrosek et al., 2008). Here, we generated titin 
constructs comprising variations of the established MuRF1 docking site as well as 
TK. A168-A170 and its C-terminally truncated variant A168A-A169 showed capable 
of binding MuRF1; while the loop mutant A168-A170ΔKTLE (where the KTLE motif 
had been mutated into a AAAA sequence), N-terminally truncated A169-A170 and 
the single A169 domain (Figure 2.9) did not display detectable interaction. 
Interestingly, when the fragment A169-A170 (which does not bind MuRF1 with 
detectable affinity) was extended to include TK, MuRF1 binding was restored and 
stronger than observed for the established A168-A170 locus (Figure 2.9a). It is worth 
noticing that the concentration of A169-TK was 10 times lower than that of the other 
constructs in the assay, indicating that TK markedly boosts the MuRF1 interaction.  
 
We further confirmed these findings via pull-down assays on skeletal muscle 
extracts (Figure 2.9b). Here, A168-A170 and A168-TK were able to pull-down the 
endogenous MuRF1 but, as before, the sample containing TK showed a stronger 
binding. Neither TK alone (either as wild-type or Y170E phosphomimic) nor the core 
domain A169 alone interacted with MuRF1 detectably (Figure 2.9a). This indicates 
that the MuRF1 docking site in M-line titin spans the region A168-TK, which 
constitutes an extended multi-domain scaffold of approx. 18-20 nm length. This 
length agrees well with the predicted dimensions of the helical domain of MuRF1, 
which is thought to fold into a long coiled-coil (Mrosek et al., 2007). Our data suggest 
that individual titin domains (or their interfaces) in this binding locus contribute 
differently to the affinity of the interaction, where a crucial high affinity locus is 
located at the A169-TK junction that is likely to play a dominant role in the 
recruitment and retention of MuRF1 in the sarcomeric M-line. 
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Figure 2.9 Dissection of TK/MuRF1 molecular interactions.  
a. Identification of the MuRF1-titin interaction region by filter binding assay. The 
helical domain of MuRF1 interacts with its established docking site A168-A170 and 
the C-terminally truncated version A168-A169, but not with the loop mutant A168-
A170ΔKTLE, the N-terminally truncated A169-A170 or the single domain A169. 
Binding to A169-A170 is restored and enhanced when TK is included in the construct 
(A169-TK); b. Pull down assay using skeletal muscle extract demonstrates that A168-
A170 and A168-TK bind endogenous MuRF1 efficiently, but that the binding is 
stronger in the presence of TK. Neither GST nor TK alone are capable to pull down 
endogenous MuRF1. 
 "
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2.4 Discussion ""
 The signaling context of TK in the sarcomere has remained elusive since its 
discovery over two decades ago (Labeit et al., 1992). Efforts to identify activators and 
substrates of this kinase have only yielded candidates of unclear physiological 
relevance. Three sarcomeric proteins have been proposed to be phosphorylation 
substrates of TK: Tcap (Mayans et al., 1998), nbr1 and p62 (Lange et al., 2005). Nbr1 
and p62 elicit weak catalysis in vitro, seemingly unrelated to their function in the TK-
signalosome (Lange et al., 2005). In contrast, Tcap induces notable levels of 
phosphorylation, being TK’s best established substrate. However, Tcap is known to 
anchor titin in the Z-disk, cross-linking the N-termini of two neighboring titin 
molecules (Zou et al., 2006) and further connecting titin to MLP and minK associated 
stretch signalling (Knoll et al., 2011, Furukawa et al., 2001). In the sarcomere, this 
Tcap-based assembly in the periphery of the Z-disk is approx. 1 µm away from TK in 
the M-line. The non-diffusible nature of both enzyme and substrate led to question the 
in vivo significance of the interaction. Here, we provide now evidence that TK is an 
inactive pseudokinase and Tcap an unlikely substrate. Our data compile the testing of 
wild-type TK, active phosphomimics (TKY170E, TKΔR2/Y170E) and inactivated variants 
(TKK36L) expressed in Sf21 eukaryotic cells and in the E. coli bacterial system. These 
TK forms were assayed for activity on Tcap as well as on inactivated extracts from 
developing myocytes and mature muscles. This did not reveal catalysis that could be 
attributed to TK, suggesting that TK was incapable of carrying out phospho-transfer. 
Structurally, we attributed this fact to two atypical residues, M34 and E147, that are 
conserved in vertebrate TKs. Each of those residues, individually, proved capable of 
disabling the highly active TK homolog, twitchin kinase. We concluded that the 
previous assignments of catalysis and substrates to TK derived from the presence of a 
contaminant kinase activity (or activities) in the insect cell preparations commonly 
employed for the production of this kinase.  
 
 The obstruction of functional studies by contaminant kinases in recombinant 
preparations from insect cells is not rare. For example, Hamel and co-workers (Hamel 
et al., 2011) found that a contaminant kinase in preparations of a substrate masked the 
activity of MAPK invalidating phosphorylation assays of the latter. A further case is 
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that of G-protein preparations, which are commonly contaminated with a lipid kinase 
(Shymanets et al., 2009). Scientifically misinterpreted, the contaminant activity was 
initially attributed to integrin-linked kinase (ILK), which later was shown to be an 
inactive pseudokinase (Fukuda et al., 2011). The study of potential catalysis in 
pseudokinases through loss of function variants can also yield notoriously misleading 
results. As examples, conventional KtoA active site mutants of BUBR1 affected the 
mitotic checkpoint (Malureanu et al., 2009, Huang et al., 2008), which was later 
shown to result from impaired conformational stability and not catalytic inactivation 
(Suijkerbuijk et al., 2012). The equivalent KtoA mutation in ILK led to renal agenesis 
during kidney development (Lange et al., 2009a), even though ILK has no catalytic 
activity and that pathogenic mutations act by impairing the structural integrity of this 
kinase (Fukuda et al., 2011). Similarly, the KtoA mutation destabilizes TK (Figure 
2.2). We propose that also here structural grounds led to previous claims of loss of 
catalysis in TKK36A variants (Mayans et al., 1998, Puchner et al., 2008, Grater et al., 
2005). 
 
 Our findings prompt the reassessment of how TK as an inactive pseudokinase 
contributes to muscle stress signaling and indicate that its hypothesized 
mechanoactivation mechanism (Puchner et al., 2008) must be revisited, as this is 
unlikely to relate to phospho-transfer activity. The hydrophobic core of protein 
kinases is organized into two “spines”: the R(regulatory) and C(catalytic) spines 
(Taylor et al., 2013). Typically, the R-spine assembles transiently during kinase 
activation. In TK, the R-spine is statically assembled into an active conformation (in 
the absence of phosphorylation in Y170 in the P+1 loop), adding to the active 
arrangement of the EFG motif and the activation loop (Temmerman et al., 2013). The 
C-spine includes residue Y107 from the αE-helix contributing to the stabilization of 
the TK fold in a permanent “pseudoactive” conformation (Figure 2.10).  
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Figure 2.10 Internal hydrophobic core architecture of PKA, TwcK and PKA. 
Residues forming C-spine are under yellow surface, R-spine under red. Residues are 
numbered according using PDB entry: a.) PKA 2CPK b.) TwcK 3UTO c.) 1TKI. 
Note the patchy arrangement of residues forming N-lobe portion of R-spine in TK. d.) 
N terminal portion αE-helix is intergrown with C-spine in TK. Molecular surface of 
TK’s R-spine is in yellow, αE-helix of TK is in pale green, PKA in teal, and TwcK in 
pink. Sidechains of corresponding residues in PKA (Y146) and TwcK (Y257) are 
lateral towards R-spine, whereas in TK (Y107) is piercing the C-spine. 
 
"""""
 41"
Thus, it is unclear how nucleotide binding –if it occurs– can lead to a switch 
response in this pseudokinase. Instead, mechanical deformations of the CRD tail 
might alter the features of the kinase surface, possibly modifying the interaction with 
its associated proteins. Pseudokinases participate in cellular pathways as regulated 
scaffolds for the assembly of signaling complexes (Boudeau et al., 2006). We show 
here that TK in its conformational ground state interacts with MuRF1. MuRF1 is 
present in low levels in the muscle cell and becomes transcriptionally up-regulated by 
myopathic stimuli including mechanical inactivity and metabolic stress conditions 
such as starvation or diabetes. This suggests that TK and MuRF1 are part of a shared 
stress-signaling pathway. Together with earlier data (Witt et al., 2005), it appears now 
that both MuRF1/MuRF2 can occupy the TK scaffold, where inactivity may cause the 
release of MuRF2 and the recruitment of MuRF1. This might result in either TK 
serving as a switch to gate MuRF1/MuRF2 signaling or TK serving as a cross-talk 
node of MuRFs pathways in function of myofibrillar stretch. This conformationally 
regulated scaffolding might constitute the primary switch mechanism of TK. 
 
Finally, the inactivity of vertebrate TK contrasts markedly with the high levels 
of in vitro catalysis of its invertebrate homologs, TwcK, TTN-1 and projectin. 
Interestingly, this difference correlates with a similar contrast in obscurin kinases, 
also members of the TK kinase family. Obscurin is located in the sarcomeric M-line, 
linking together the sarcoplasmic reticulum (Lange et al., 2009b), titin (Bang et al., 
2001) and the thick motor filaments (Kontrogianni-Konstantopoulos et al., 2004) 
Obscurin (and the invertebrate homolog UNC-89) contains two kinases, PK1 and 
PK2. In vertebrates, PK1 and PK2 have canonical active sites and are catalytically 
active (Hu and Kontrogianni-Konstantopoulos, 2013, Mayans et al., 2013). In 
invertebrates, PK1 is inactive or has modified its activity as it lacks identifiable 
catalytic residues; and PK2 has a degenerated active site indicating that its activity 
might be modest (Mayans et al., 2013). This inverse correlation in the catalysis of 
kinases from titin-like and obscurin-like filaments in vertebrate/invertebrate suggests 
a correlated co-evolution of giant protein kinases (Figure 2.11). It is tempting to 
speculate that in vertebrates, the inactivation of TK was coupled to a co-activation of 
the obscurin kinases. Thus, stretch-activated phospho-transfer seems to reside today 
in different filament systems in muscles across animal phyla. Future studies in these 
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muscle kinases are required to understand their patterns of activity and scaffolding in 
terms of muscle responses to stress stimuli. "
Figure 2.10 Distribution of active kinases and inactive pseudokinases in titin-like 
filaments from vertebrate and invertebrate muscle 
For each filament the following domains are shown: Ig (blue circles); Fn3 (green 
circles); active kinases (magenta boxes); inactive pseudokinases (grey boxes). 
Pseudokinases where inactivity cannot be reliably predicted are indicated with a 
question mark. The conservation of the Ig-Ig-Fn3-(pseudo)kinase domain 
arrangement is present independently of kinase catalytic properties.  ""
 
""
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Chapter 3 
!
Genetic perturbation of the evolutionary conserved 
motif bridging titin kinase and MuRF1 signaling 
platforms leads to dilated cardiomyopathy   "
3.1 Introduction "
Titin has been frequently predicted to participate in stress signaling since the 
titin filament can sense sarcomeric strain that induces conformational changes within 
its polypeptide chain. In particular, mechanical models of stretch-activation have been 
proposed for the titin kinase (TK) domain that is evolutionarily conserved among 
titin-like myofilaments. Located at the C-terminus of the molecule, TK belongs to the 
myosin light chain kinase family of non-RD-kinases (Mayans et al., 1998). 
Experimental evidence underscores the critical role of TK in sarcomere maintenance. 
Deletion of TK enclosing M-band titin in mice is embryonically lethal due to failure 
in heart development (Weinert et al., 2006) or causes terminal cardiomyopathy when 
postnatally induced (Gotthardt et al., 2003). However, the TK-mediated signaling 
pathways are still poorly understood. In vitro studies of differentiating myocytes 
implicate TK-mediated phosphorylation of telethonin (TCAP) in the reorganization of 
the cytoskeleton during myofibrillogenesis (Mayans et al., 1998). In mature muscle, 
TK was proposed to act as a scaffold for assembly of the autophagic machinery 
complex, comprising nbr1, p62 and the E3 ubiquitin ligase MuRF2. This signalosome 
was suggested to act as a muscle activity sensor; upon mechanical inactivity the 
complex disbands and MuRF2 translocates to the nucleus where it excludes nuclear 
serum response factor and causes the repression of transcription (Lange et al., 2002). 
To date, all TK activity-regulating events have been identified in the catalytic domain, 
however, the neighbouring domains of many kinases are known to play a regulatory 
role. For example, the catalytic activity of twitchin kinase (TwcK), an invertebrate 
homologue of TK, has been shown to be regulated through a linker sequence N-
terminal to the kinase domain (NL) (von Castelmur et al., 2012). In vertebrates, a 
binding site for the E3 ubiquitin ligases, MuRFs, is located N-terminally to the TK 
domain, formed by the evolutionary conserved tandem of IgA168-IgA169-FnIIIA170, 
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hereby A168-A170. It was consistently demonstrated that only MuRF1 is directly 
interacting with the A168-A170 repeat (Center et al., 2001, Witt et al., 2005, Mrosek 
et al ., 2008) whereas other two family members MuRF2 and MuRF3 might associate 
with titin filament indirectly (Centner et al., 2001, Lange et al., 2005). Functionally 
MuRF1 was shown to mediate muscle catabolism either through direct targeting of 
sarcomere components such as troponin I (Kedar et al., 2004), myosin heavy chain 
(Clarke et al., 2007) or muscle actin (Polge et al., 2011) to degradation by ubiquitin-
proteasome pathway or indirectly by regulating gene expression machinery (Willis et 
al., 2007, Wadosky et al., 2014, Willis et al., 2014), muscle energetics (Willis et al., 
2009, Hirner et al., 2008), protein kinase Cε (Arya et al., 2004) or acetylcholine 
receptors (Rudolf et al., 2013, Khan et al., 2014). However, the functional basis of 
MuRF1-TK interaction remains elusive. It was demonstrated that overexpression of 
MuRF1 disrupts the binding region of titin (McElhinny et al., 2002), but there are no 
indications, that titin could be a substrate for the ubiquitin ligase activity of MuRF1 
(Kedar et al., 2004), implying other than a simple enzyme-substrate relation between 
MuRF1 and titin. 
 
To explore the possibility of crosstalk between TK and MuRF1 signalling 
pathways, we have determined the crystal structure of human TK together with its 
flanking domains (A170-TK-M1). We then investigated the molecular consequences 
of a rare SNP, rs200675195, in the NL (N-terminal linker connecting A170 and TK) 
segment corresponding to the mutation D24728V3, found in a small family affected 
by dilated cardiomyopathy (DCM). The mutation increases interdomain flexibility, 
resulting in enhanced MuRF1-dependent ubiquitination of TK. Together with the 
previous identification of MuRF1 as a myocardial anti-hypertrophic gene (Witt et al., 
2008, Chen et al., 2012, Willis et al., 2007), our results suggest that genetic 
perturbation of the A170-TK /MuRF1 complex is likely to affect myocardial 
trophicity, and that this is a probable disease mechanism in the hereditary 
cardiomyopathy here reported. 
 
 
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
3 Residue numbering is based on titin protein entry NP_003310.4. For simplicity, throughout the text 
this mutation will be referred to as “DtoV”. 
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3.2 Materials and Methods ""
3.2.1 Protein cloning and expression "
A list of protein constructs used in this study is presented in Table 3.1. 
Recombinant samples for crystal structure determination, NMR, SAXS and GST-
pulldown were produced in E.coli as described (Bogomolovas et al., 2009). 
Constructs containing TK were expressed in SoluBL 21 (Genlantis), others in BL21 
Star (Novagen) cells.  
 
For adenovirus production A168-TKWT and A168-TKDtoV were cloned into 
pET-GST1a vector (Bogomolovas et al., 2009). This vector fuses a His6-tagged GST 
and a TEV (tobacco etch virus) protease cleavage site N-terminally to the target 
construct. The fusion was then cloned into the adenovirus production vector DUAL-
CCM(+) and RGD-modified fiber knob recombinant adenoviruses were commercially 
produced and purified (Vector Biolabs). 
 
For MuRF1 expression in mammalian cells, the pEGFP-C1 vector was used. 
Open reading frame of EGFP was replaced with MuRF1 through NheI-NotI 
restriction sites. 
Twitchin kinase constructs were produced as described (von Castelmur et al., 2012). 
DtoV exchange in NLTwcKCRDDtoV was introduced through overlap extension PCR. 
All constructs were verified by sequencing. 
 
 46"
Table 3.1 Protein constructs 
 
Construct 
Reference 
sequence, residue 
numbers and 
applied changes 
Description 
A170-M1WT NP_003310; 
Res. 24622-25160 
Wildtype titin kinase domain surrounded by 
neighbouring fibronectin (A170) and immunoglobulin 
(M1) domains. 
A170-M1DtoV NP_003310; Res. 24622-25160; 
Asp24728Val 
Mutant titin kinase domain surrounded by 
neighbouring fibronectin (A170) and immunoglobulin 
(M1) domains. 
A170-TKWT NP_003310; 
Res. 24622-25068 
Wildtype titin kinase domain with preceding 
fibronectin domain 
A170-TKDtoV NP_003310; Res. 24622-25068; 
Asp24728Val 
Mutant titin kinase domain with preceding fibronectin 
domain 
A168-TKWT NP_003310; 
Res. 24430-25068 
MuRF1 binding site  extended with wildtype TK 
domain 
A168-TKDtoV NP_003310; Res. 24430-25068; 
Asp24728Val 
MuRF1 binding site extended with mutant TK domain 
TKWT NP_003310; 
Res. 24747-25068 Wildype TK core 
A168-NLWT NP_003310; 
Res. 24430-24731 MuRF1 binding site with NL of wildtype TK 
A168-NLDtoV NP_003310; Res. 24430-24731; 
Asp24728Val 
MuRF1 binding site with NL of mutant TK 
 
A170-NLWT NP_003310; 
Res. 24622-24747 Fibronectin domain with wildtype N-terminal linker 
A170-NLDtoV NP_003310; Res. 24622-24747 
Asp24728Val 
 
Fibronectin domain with mutated N-terminal linker 
 
GST-MuRF1cc NP_115977"
Res. 169-327 Coiled-coil region of MuRF1 fused to GST 
MBP-MuRF1 NP_115977 Full length human MuRF1 fused to MBP 
TwcKCRD NP_502274.2; 
Res. 6245-6581 C.elegans twitchin kinase domain with CRD 
NLTwcKCRD NP_502274.2; 
Res. 6205-6581 C.elegans twitchin kinase domain with NL and CRD 
NLTwcKCRDDtoV 
NP_502274.2; 
Res. 6205-6581; 
Asp6235Val 
Mutant C.elegans twitchin kinase domain with NL and 
CRD ""
3.2.2 Crystal structure determination "
Crystals of A170-M1WT were grown in 2 µL hanging drops at 20 °C obtained 
by mixing protein solution and mother liquor (12% PEG 4K, 0.1 M Tris pH 7.5, 50 
mM NaCl, 30% glycerol, 5 mM L-proline) in equal proportions. For X-ray data 
collection crystals were flash frozen in mother liquor. Diffraction data were collected 
on I04-1 beamline at Diamond Light Source (Didcot, UK) using PILATUS 2M 
photon counting detector (Dectris, Baden, Swizerland) at 0.91730 Å wavelength. In 
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total 180 images were collected with 4.5 s exposure time, 1 ° oscillation and detector 
distance of 297 mm.   Data and model refinement statistics are listed in Table 3.2. For 
merging statistics anomalous pairs were kept separate. Phasing was done by 
molecular replacement in Phaser (McCoy, 2007) using TK (PDB entry 1TKI, Mayans 
et al., 1998), the A170 Fn3 domain (PDB entry 2NZI, Mrosek et al., 2007) and the 
M1 Ig domain (PDB entry 2BK8) as search models. Manual rebuilding was in COOT 
(Emsley et al., 2010). The model was refined and the solvent built in PHENIX 
(Adams et al., 2011).  
 
Table 3.2 X-ray data statistics and model refinement parameters 
 
 A170-M1WT 
Space group P 21   
Cell dimensions    
    a, b, c (Å) 63.61, 184.65, 66.08 
    a, b, g  (°)  90, 116.6, 90 
Solvent content (%) 55.16 
Matthews coef. (Å3/Da) 2.74 
Copies in asu 2 
Data collection  
X-ray source DIAMOND I04-1 
Detector PILATUS 2M 
Wavelength (Å) 0.91730 
Resolution (Å) 29.54-2.39 (2.48-2.39) 
No.unique reflections 52551 (5292) 
Rsym(I) (%) 13.2 (72.2) 
I / sI 8.47 (1.54) 
Completeness (%) 97.8 (98.7) 
Redundancy  3.4 (3.3) 
Refinement  
Resolution (Å) 29.54-2.39 
Rwork / Rfree(%) 18.92 / 24.68 
No. atoms 8870 
    Protein 8666 
    Water 204 
B-factors  
    Protein 49.2 
    Water 45.5 
R.m.s. deviations  
    Bond lengths (Å) 0.009 
    Bond angles (°) 1.26   
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3.2.3 Exome sequencing  "
 Genomic DNA was extracted from buffy coat using a commercial kit (Qiagen) and 
exome sequencing was performed on two affected subjects. The patients in this study 
were identified from a standardized DCM cohort (Knoll et al., 2006). Sequencing was 
performed commercially (BGI Americas). Adapters were ligated to shared genomic 
DNA, amplified by ligation mediated PCR, purified and hybridized to custom 
NimbleGen array for enrichment. Captured fragments were sequenced on a high 
throughput HiSeq2000 platform. Raw image files were processed by Illumina base 
calling Software 1.7 for base calling with default parameters and the sequences of 
each individual were generated as 90bp paired-end reads. Further reads were 
processed and variants called using two independent workflows: GATK(DePristo et 
al., 2011, McKenna et al., 2010) and DNAnexus implemented in DNAnexus cloud-
based data analysis and management platform for DNA sequencing data. Variants 
shared between both subjects were further filtered using against dbSNP135 and the 
1000 Genome project to exclude previously identified disease irrelevant SNPs using 
wANNOVAR (Chang and Wang, 2012). Genetic variations in DCM gene list (Meder 
et al., 2011) were reported. Identical results was obtained using both data processing 
pipelines. 
 
3.2.4 NMR studies "
For NMR titration studies A170-NLWT and A170-NLDtoV were uniformly 15N 
labeled in M9 medium as described (Bogomolovas et al., 2009) and titrated with 
unlabelled TKWT. 1H15N heteronuclear single quantum correlation spectra were 
recorded at 22 °C in 20 mM Tris pH 7, 50 mM NaCl, 0.5 mM TCEP on Bruker 700 
MHz spectrometer equipped with cryogenic triple-resonance probes. Spectra were 
processed with Topspin. "
3.2.5 X-ray solution scattering "
SAXS data were collected on the P12 beamline (λ=0.124 nm) at the Petra III 
storage ring (EMBL, DESY, Hamburg) using a 2D photon counting Pilatus 2M pixel 
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X-ray detector (Dectris, Switzerland). Data were processed and reduced using the 
ATSAS software package (Petoukhov et al., 2007). Radiation damage, monitored by 
repetitive 1 sec exposures, was negligible. Were applicable replicated measurements 
were averaged using PRIMUS (Konarev et al., 2003) and curves at several protein 
concentrations merged using ALMERGE (Franke et al., 2012). Radiuses of gyration 
(Rgyr) (alternatively calculated based on Guinier approximation using AUTORG, 
Petoukhov et al., 2007), maximum particle dimensions (Dmax), and pair distribution 
functions (P(r)) were calculated using the indirect transform package DATGNOM 
(Petoukhov et al., 2007). The molecular weight was estimated from SAXS profiles 
using the Porod volume based MoW server (Fischer et al., 2010)  "
3.2.6 Cell culture 
  
H9C2 rat cardiomyocytes were grown in DMEM/10% FCS/1X IST and 
antibiotics on gelatin coated 10 mm dishes. For differentiation into myotubes cells 
were allowed to reach confluence and then grown for 7 additional days in DMEM 
supplemented with 1% FCS and 1 mM all-trans retinoic acid. Myotubes were 
transfected at 100 MOI with recombinant adenovirus expressing wildtype or DtoV 
mutant GST-A169-TK and when indicated transfected with MuRF1 expressing 
plasmid using TurboFect reagent (Fisher Biosciences) according to manufacturer 
recommendations. After 24 hours cells were lysed in PBS+ 0.2% NP-40 + 2 mM DTT 
and protease inhibitors and clarified supernatant was purified on glutathione resin. ""
3.2.7 GST-Pulldown with recombinant proteins!"
Approximately 50 µg each of GST-A168-NLWT, GST-A168-NLDtoV and GST-
MuRF1 were immobilized on 30 µl of Glutathione-Sepharose-beads and washed once 
with PBS + 0.1% NP40. Purified His6-MBP-MuRF1 was diluted 20-fold in PBS 
supplemented with 0.1% NP40. After centrifugation for 10 min at 14000g, the volume 
corresponding to 20 µg His6-MBP-MuRF1 (approximately 500µl) was then added to 
each of the three tubes. The tubes were then incubated for 2-3 hours at 4°C under 
light movement. After spinning for 1 min at 3000g supernatants were removed and 
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the beads washed either 1x with 1 ml PBS or 1x with 1 ml PBS + 0,1% NP40 and 1x 
with 1 ml PBS. Supernatants were completely removed, and the beads were directly 
resuspended in SDS sample buffer. The supernatant was completely removed and 30 
µl of  1.3x  LDS Sample Buffer (Invitrogen) added to the beads. After 10 min 
incubation at 70°C the supernatant was transferred to a fresh tube and then separated 
on 4-12% Bis-Tris gels (Invitrogen). "
3.2.8 Western Blot "
After separation on 4-12% Bis-Tris Gels proteins samples were transferred 
onto a nitrocellulose membrane, which was subsequently blocked in TBST/5%BSA. 
After washing the membrane 2x in TBST the filter was incubated for 2h with anti-
human TK (Myomedix, Mannheim, Germany) at a concentration of 0.5µg/ml in 
TBST/5%BSA. The membrane was washed three times in TBST, incubated for 1h in 
TBST containing goat anti-rabbit IgG conjugated to alkaline phosphatase at 1:1000 
dilutions (Dako, Glostrup, Denmark).  After 3 washes in TBST and a final wash in 
TBS, the detection with NBT/BCIP was done as described by the supplier (Roche 
Diagnostics). 
 
Alternatively membranes were incubated with Cy3-labelled anti-rabbit-IgG 
(Jackson) as a secondary antibody at a concentration of 0.5µg/ml. Incubation and 
washes were performed as described above. The membrane was then dried and 
scanned with an FLA-5100 fluorescent image analyser (Fuji). 
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3.3 Results ""
3.3.1 Crystal structure of A170-M1 reveals structural basis of 
MuRF1 and TK crosstalk.  "
We have elucidated the crystal structure of the human titin kinase region 
A170-M1 that spans both up- and downstream neighbouring domains and the 
respective linker sequences (Figure 3.1). The structure at 2.46 Å resolution reveals 
that the kinase domain is enwrapped by both the N- and C-terminal linker sequences 
with fibronectin A170 and immunoglobulin M1 domains projecting from the 
assembly (Figure 3.1b).  
 
Figure 3.1 Crystal structure of A170-TK-M1 
a. Schematic representation of TK environment. Domains are coloured as in crystal 
structure, additional domains forming the MuRF docking platform are represented in 
dashed lines. b. Overall crystal structure of A170-M1WT; Fn3 domain A170 is in blue, 
N-terminal linker is in yellow, kinase core is represented as grey molecular surface, 
C-terminal regulatory tail is in green and Ig domain M1 is in red. D24728 is represented 
as a purple sphere.  "
""
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In excellent agreement with previous data (Mayans et al., 1998), the C-
terminal tail domain (CRD) wraps around the larger kinase C-lobe, deeply penetrating 
the catalytic cleft. The N-terminal linker (NL) is 23 residues long and straddles the 
back of the N-terminal kinase lobe, packing against the hinge region in a similar 
fashion to that of the equivalent fragment in the invertebrate twitchin kinase (von 
Castelmur et al., 2012). In titin kinase, however, the NL forms a prominent α-helix in 
its junction to domain A170. The structure shows that this NYD motif mediates a 
number of interactions that secure the packing of the NL segment to the kinase 
domain (Figure 3.2a). In particular, the lateral carboxyl group of Asp24728 is buried in 
the interface of the kinase domain, where it engages in two hydrogen bond 
interactions with i) the lateral hydroxyl group of Ser24831 that is located in a loop 
between the α-helix C2 and β-strand C5 and ii) the amino backbone group of Arg24885 
located in the loop between β-strands C7 and C8. The rest of the NL segment interacts 
with the kinase core only loosely (Figure 3.3a), and in fact structural differences are 
observed in this region between the two asymmetric unit copies (Figure 3.3b).  
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Figure 3.2 NL region orchestrates domain arrangement and acts as a spacer 
between two MuRF1 binding sites 
a. Close-up of the NL-TK interaction. D24728 is located at the helical region of the N-
terminal linker, making hydrogen bonds with the Ser24831 and Arg24885 and thus 
attaching the N-terminal linker to the kinase core. b. Dissection of MuRF1-titin 
interaction using a fluorescent binding assay. The helical domain of MuRF1 binds to 
established site A168-A170 and has affinity to the kinase domain itself, whereas NL 
acts as a repellent for MuRF1 and reduces the binding. 
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These findings indicate that the NYD motif crucially contributes to the 
packing of the NL segment against the kinase domain. MuRF1 binds a tandem of 
three Ig-like domains, A168-A170, immediately preceding the TK domain (Centner et 
al., 2001). The binding is mediated by the C-terminal helical domain of MuRF1 and is 
deterministically influenced by the presence of a loop with sequence KTLE in the titin 
domain A169 (Mrosek et al., 2007, Muller et al., 2007). However, TK domain and NL 
have not been considered as an integral part of the MuRF1 binding site previously. 
Motivated by the compact domain arrangement in the A170-M1 structure, we 
evaluated the possible contribution of NL and TK to the MuRF1 binding surface 
(Figure 3.3b). In excellent agreement with published data, A168-A170 is capable of 
binding MuRF1. Interestingly, we observed that inclusion of NL to the known A168-
A170 binding site (construct A168-NL) or TK (construct NL-TK) significantly 
reduced MuRF1 binding. Consequently, combination of both MuRF1 affinity regions 
A168-A170 and TK in construct A168-TK had no additive effect, as repellent NL was 
included. Taken together, these results indicate that the MuRF1 binding site spans the 
region A168-TK, consisting of two affine regions brought together through the 
repellent NL. 
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Figure 3.3 Interactions between NL and TK.  
a. Specific Interactions were analysed using YASARA software. Note that mainly 
beginning (where D31225V is located) and the end of the NL are specifically 
interacting with TK. b. Superimposition of the two molecular copies of A170-M1 in 
the crystallographic asymmetric unit. Both ribbon thickness and colouring correspond 
to the RMSD values of the superimposition as given in the accompanying scale, 
where minimum, maximum and average RMSD values are shown. The structural 
agreement is overall excellent except for the differences in the middle of NL. 
"
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3.3.2 Structural context of D24728 is conserved among the titin-like 
myofilaments "
The crystal structure of A170-M1 implied that compact A170 and TK domain 
arrangement is influenced by D24728 located in the helical region of NL. Examination 
of primary NL sequences revealed remarkable conservation of the discussed aspartate 
residue among titin-like filaments in the animal kingdom (Figure 3A). The 
conservation of this linear motif is reflected in its preserved 3D context. 
Superimposition of corresponding structures of human TK region and the C. elegans 
titin-like filament, twitchin, (PDB 3UTO5) revealed that the structural context of 
D24728 is highly similar (Figure 3.4). Taken together, D24728 and homologous 
aspartates in titin-like filaments are under strong evolutionary pressure for 
conservation. "
 
Figure 3.4 Helical region of NL is highly conserved among the titin-like 
myofilaments 
a. D24728 is highly conserved in the titin kinase family. b. Superimposition of human 
TK (this work) and twitchin from C. elegans (PDB 3UTO5) reveals that the structural 
context of D24728 is highly preserved between the human and worm proteins (residue 
numbering follows the PDB entry). 
 
3.3.3 Rare SNP rs200675195 in NL is associated with hereditary 
dilated cardiomyopathy""
Outstanding preservation of D24728 among titin-like myofilaments led us to 
speculate on the detrimental effects of mutations at this position. SNP rs200675195 
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causing D24728 mutation to valine was found in the short genetic variation database 
dbSNP. Within a large meta-cohort4 of assembled exome sequences this allele was 
found in 5 from a total of 12031 sequenced individuals, resulting in a minor allele 
frequency (MAF) of 0.02%. In NHLBI GO Exome Sequencing Project cohort, that is 
enriched in individuals with heart, lung and blood disorders, this allele was also found 
5 times, corresponding to roughly 1 of 2,500 patients (yielding a higher MAF of 
~0.04%). The higher MAF of rs200675195 in NHLBI GO Exome Sequencing Project 
cohort compared to larger unbiased meta-cohort implies that this mutation is 
associated with heart, lung and blood disorders. Consistent with this idea, available 
SNP effect predicting algorithms (SIFT 23, PROVEAN 24, Polyphen-225) predict DtoV 
to be damaging. To further test this hypothesis, we performed direct sequencing of the 
TK-encoding titin exon in 200 cardiomyopathy patients 26. This also identified 
rs200675195 in one patient diagnosed with severe DCM. Furthermore, presence of 
this allele was predictive for the disease in the available small family tree (Figure 
3.5a and 3.5b), since a daughter was found to be heterozygous for the DtoV mutation 
and suffered from heart disease.  
!
""""""""""""""""""""""""""""""""""""""""""""""""""""""""
4 http://genome.sph.umich.edu/wiki/Exome_Chip_Design 
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Figure 3.5 Rare SNP rs201763096 causing D24728V exchange is associated with 
dilated cardiomyopathy 
a. DtoV mutation in a DCM family (+/- indicates heterozygosity for the mutation; 
arrow indicates index patient; grey indicates unknown clinical status; open squares or 
circles: unaffected, black circles or squares indicate affected; age at death in brackets;  
slash indicates deceased; roman numbers indicate # of generations studied; arabic 
numbers indicate patients. b. Clinical characteristics. c. Summary of identified genetic 
variants.  
 
 
"
Finally, we sequenced whole exomes of the two DtoV patients to search for 
other genetic variants associated with DCM; the DtoV allele may only cause disease 
as a compound heterozygote, or might not be the disease-causing allele in the first 
place. In both analyzed patient exomes, the set of known DCM associated genes27,28 
had good sequence coverage (Figure 3.6). After variant calling and filtering, two 
shared heterozygous variants in DCM associated genes were identified; the 
aforementioned DtoV allele in TK and a second variant in nexilin. The nexilin variant 
frequency was above the proposed cut-off for pathogenic DCM mutations28 and was 
predicted to be benign (Figure 3.5c).  
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Figure 3.6 Mean exon coverage for the DCM genes. Average exon coverage for 
patient II-2 is shown in red, for patient III-1 in black. All genes were sequenced with 
sufficient sequencing depth for reliable genetic variant calling.  ""
!"
In summary, our sequencing data predict that individuals with the rare SNP, 
rs200675195, have and increased likelihood of suffering from DCM. Future studies 
with larger families will be required to formally prove this association, or to test for 
additional alleles acting as compound heterozygotes.""
3.3.4 The D24728V mutation impairs the structure of extensive 
regions of the MuRF1 binding site "
Our data indicated that rare SNP, rs200675195, may be involved in the 
pathogenesis of human DCM. In the DtoV exchange caused by the studied SNP, the 
small hydrophobic residue introduced is incapable of hydrogen bonding through its 
side chain and is likely to impair the binding of the NL segment against the kinase 
core. We predicted that this destabilizes the packing of the full NL segment, possibly 
disrupting the connection between high affinity binding sites of MuRF1 on titin. 
Structurally, the DtoV mutation occurs within the segment that links TK to its 
preceding Fn3 domain, A170, which is a part of the MuRF1 binding site on titin21, 22.  
Therefore, we hypothesized that the DtoV mutation might impair the packing of the 
NL against TK. To address this question we performed in vitro NMR titrations using 
15N labelled A170-NL and unlabelled TK (Figure 3.7a and 3.7b). We speculated that 
if in a single polypeptide chain NL and TK interact with each other, then upon 
splitting them into two separate chains they would bind to each other. Experimentally 
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we could confirm that after splitting, A170-NLWT interacts with TK, as demonstrated 
by the chemical shift perturbations in HSQC spectra overlays (Figure 3.7a). Overlay 
of A170 and A170-NL spectra indicated that mainly resonances from NL residues are 
perturbed, implying nativity of the observed interaction (Figure 3.8). However, when 
TK was titrated with A170-NLDtoV no chemical shift perturbations were observed 
(Figure 3.7b), indicating no interaction between proteins. Consistent with this 
observation, multiple structural perturbations are seen in the NL region when spectra 
from A170-NLWT and A170-NLDtoV are superimposed (Figure 3.8). In conclusion, 
NMR data indicate that DtoV substitution causes structural perturbation, resulting in 
abolishment of NL attachment to the TK core.  
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Figure 3.7 Structural consequences of DtoV exchange. 
a. HSQC-monitored titration of A170-NLWT with increasing concentrations of TKWT 
(red, green, magenta). Black arrows indicate the major peak shifts. b. HSQC spectra 
overlay of A170-NLDtoV (red) and in presence of TKWT (magenta) reveal no peak 
shifts. c. SAXS-derived molecular parameters; Dmax, Rgyr, Vporod and MW denote 
maximal dimension, radius of gyration, Porod volume and molecular weight, 
respectively. MWcalc derived from scattering curve, MWtheor based on primary 
sequence. d. Distance distribution functions of A170-TKDtoV and A170-TKWT. e. 
Dimensionless Kratky plot of A170-TKDtoV and A170-TKWT scattering curves. 
Intersection of black lines indicates expected maximum position for a fully rigid 
globular protein (that follows Guinier’s law I(q) = I(0) exp (−(qRgyr)2/3)).  
 
"
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Figure 3.8 Effect of D31225V mutation on NL. HSQC spectra overlay of solely 
A170 domain (red) and A170-NL constructs: wildtype (blue) and mutant (green) 
(both wildtype and mutant versions). The Asp to Val mutation alters those chemical 
shifts that arise from the linker residues (indicated in square). Multiple structural 
perturbations caused by the mutation indicate major effects on the A170-NL segment. ""
"""
In order to gain an insight into the effect of the DtoV mutation on interdomain 
organization, we performed SAXS measurements on A170-TKDtoV and A170-TKWT. 
A larger radius of gyration and increased maximal particle dimension indicated a 
change in conformation caused by the mutation (Figure 3.7c). To evaluate possible 
differences in interdomain flexibility caused by the DtoV mutation, SAXS data were 
presented in a dimensionless Kratky plot (Figure 3.7d), allowing for direct 
comparison of objects of different shape and size. In this representation a rigid 
globular protein would provide a bell shaped curve with a maximum value of ~ 1.1 
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(3*exp(-1)) at ~ 1.75 ( ), whereas completely flexible unfolded protein would yield 
a curve that gradually increases to a constant value of 2.  Both WT and mutant A170-
TK show broadening of a bell shaped curve and shift of a maximum towards higher 
qRgyr values, expected for the scattering of proteins with structured domains linked by 
flexible linkers29,30. The scattering curve of A170-TKDtoV, when compared to wildtype 
is broader and its maximum is further shifted towards high qRgyr values, consistent 
with a more flexible domain conformation in this mutant. These findings are at least 
partially reflected in the pair distribution function (P(r)), which represents the 
histogram of distances between scattering volumes within the molecule (Figure 3.7e). 
Taken together, our data indicate that the DtoV mutation is sufficient to impair 
binding of NL to TK, resulting in increased interdomain flexibility between the 
previously characterized MuRF1 binding site and TK.  
 "
3.3.5 The D24728V mutation causes activation of homologous C. 
elegans kinase 
 
In order to validate the observed effects of DtoV substitution we chose C. 
elegans twitchin kinase (TwcK) as a model. TwcK is a well-characterized 
invertebrate homologue of human TK, with which it shares high sequence and 
structural similarity (RMSD for C. elegans TwcK and human TK is 1.29 Å, 34 % 
sequence identity). Moreover, the role of the NL segment as an intrasteric inhibitor of 
TwcK catalysis is well characterised (von Castelmur et al., 2012). In contrast, 
recombinant TK preparations are essentially inactive without a dual activation 
process1 that is not fully understood and the physiological TK substrates in the heart 
are not known. We have introduced the DtoV mutation in C. elegans TwcK and 
measured the phosphotransfer activity (Figure 3.9). NLTwcKCRD containing both 
inhibitory regions exhibits negligible activity, but upon DtoV mutation 
(NLTwcKCRDDtoV) the catalytic activity is restored to levels comparable to those of 
constructs lacking the NL (TwcKCRD). This supported our conclusions that DtoV 
translates into altered interactions between the NL and the kinase core, resulting in 
significant release of the inhibitory NL. 
 
 "
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Figure 3.9 Effect of DtoV exchange on titin-like protein from C. elegans.  
a. A solid phase paper assay was used to quantify phosphorylating activity of twitchin 
kinase variants. b. Quantification of P81 paper phosphotransfer assay results. 
NLTwcKCRD containing both inhibitory regions demonstrates only a trace amount of 
catalysis.  Introduction of the DtoV mutation in NLTwcKCRD (NLTwcKCRDDtoV) 
augments kinase activity and catalysis levels become comparable to TwcKCRD 
containing only the C-terminal regulatory element.  
 
 ""
3.3.6 D24728V mutation enhances the interaction with MuRF1 and 
TK ubiquitination in vivo "
Our investigations strongly imply the pathogenic nature of DtoV mutation by 
demonstrating the disruption of NL functionality. As NL was found to act as an 
inhibitor of MuRF1 binding, we have tested the effect of DtoV mutation on MuRF1 
affinity. We have found that the DtoV mutation abolishes NL inhibitory effect on 
MuRF1 binding to A168-NL construct in GST pulldown assays using recombinant 
proteins; mutant A168-NL binds MuRF1 more strongly than the wildtype (Figure 
3.10a). In order to evaluate the functional relevance of this observation in vivo, we 
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expressed GST tagged A168-TKWT or A168-TKDtoV and MuRF1 in differentiated rat 
cardiac myocyte H9C2 cells. Overexpression of MuRF1 resulted in reduced levels of 
A168-TKDtoV, but did not affect wildtype protein levels (Figure 3.10b). To determine 
if the reduction in mutant protein levels was mediated via the ubiquitin proteasome 
pathway, we treated A168-TKDtoV overexpressing cells with the cell permeable 
proteasome inhibitor MG-132. Proteasome inhibition rescued levels of mutant A168-
TK in soluble fractions (Figure 3.10c). However, we observed significant 
accumulation of A168-TKDtoV in insoluble fractions (Figure 3.10c), suggesting that 
the ubiquitin proteasome pathway is needed for removal of possibly misfolded A168-
TKDtoV. We conclude that the DtoV mutation within an A168-TK context enhances 
binding to MuRF1 in vitro and results in reduced protein levels due to enhanced 
degradation through the ubiquitin proteasome pathway in H9C2 cells. 
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Figure 3.10 DtoV exchange alters TK and MuRF1 interaction. a. Recombinant 
A168-NLDtoV interacts more strongly with MuRF1 than WT construct in GST 
pulldown assays. b. Overexpression of MuRF1 in differentiated H9C2 rat cardiac 
myocytes reduced both total and purified quantities of GST-tagged A168-TKDtoV 
fusion peptides as shown by Western blots with TK-specific antibodies.  c. The 
proteasome inhibitor MG-132 partly restored MuRF1-induced A168-TKDtoV protein 
depletion as shown by Western blots with TK-specific antibodies. In addition, 
proteasome inhibition by MG-132 caused accumulation of A168-TKDtoV in the 
insoluble fraction, probably corresponding to misfolded proteins. ""
"
3.4 Discussion "
The crystal structure of A170-M1 reveals an unexpected crucial role of a 23-
residue NL linker motif for MuRF1 and TK crosstalk. The MuRF1 binding site in 
A168-A170 6,22 and a newly discovered affinity region in TK are brought into close 
proximity by NL, which wraps around the N-lobe of the kinase, thus reducing the 
distance between two signaling platforms. The observed packing mainly arises from 
interactions between the highly conserved helical NYD motif located in a junction 
between the A170 domain and TK. Intriguingly, a rare SNP, rs200675195, results in a 
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D24728V exchange precisely in this motif. To date, the NHLBI GO Exome 
Sequencing Project has identified rs200675195 in 5 individuals. The here-represented 
cohort is enriched in samples from patients with heart, lung and blood disorders. 
Unfortunately we were not able to obtain clinical characteristics of these patients. 
However, structural analysis of DtoV effects by NMR and SAXS demonstrated that 
this exchange increased interdomain flexibility and abolished NL-TK interaction and 
thereby releasing the inhibitory NL effect in the homologous invertebrate TwcK. 
Taken together, our structural observations point to the pathogenicity of the DtoV 
mutation, adding to the evidence accumulated in recent years that mutations in TTN 
are an important genetic contributor to DCM (Gerull et al., 2002, Gerull et al., 2006, 
Hermann et al., 2012).   
 
To explore the pathogenic nature of the DtoV exchange we have sequenced 
the TTN exon 358 from 200 cardiomyopathy patients. This exon encodes TK and a 
binding site for MuRF1 in the section immediately N-terminal to the kinase. Our TTN 
genetic screen identified rs200675195 co-segregating with the disease in a small 
family affected by DCM. The second genetic variation in a gene possibly linked to 
DCM, rs201763096 as identified by whole exome analysis in nexilin, has a frequency 
above the proposed cut-off for pathogenic DCM variants and was predicted to be 
benign. However, future studies will need to address the relative contributions of 
DtoV and rs201763096, because individuals carrying more than one rare (MAF <1%) 
sarcomeric allele have a higher risk of adverse cardiovascular events (Bick et al., 
2012). 
 
At the molecular level we have found that DtoV abolishes the inhibitory effect 
of NL and results in enhanced MuRF1 binding. The latter translates in vivo into 
enhanced MuRF1-mediated titin degradation by the ubiquitin-proteasome pathway. 
Speculatively, increased ubiquitination could result from both enhanced binding and 
increased flexibility between two MuRF1 affine modules, A168-A170 and TK, 
resulting in misubiquitination of TK surface lysines that would be otherwise 
inaccessible for MuRF1 in rigid WT protein.   This phenomenon per se could lead to 
the accumulating loss of mutant titin, resembling the findings in the Herman et al. 
(2012) study where nonsense mutations of titin were identified as a major mutational 
group possibly causing DCM through haploinsufficiency or by means of a dominant 
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negative mechanism. Furthermore, we have found that A168-TKDtoV accumulates in 
insoluble aggregates when the ubiquitin-proteasome pathway is inhibited, indicating 
that mutant titin might have a folding defect and active removal of misfolded proteins 
is needed to prevent the pathological accumulation of aggregates. This pathway 
resembles the clinical findings in autosomal dominant inclusion body myopathy 
associated with Paget disease of the bone and frontotemporal dementia (IBMPFD) 
patients. IBMPFD is a late-onset genetic multisystem disorder leading to dilated 
cardiomyopathy with inclusion bodies formed of ubiquitinated mutant protein 
(Hubbers et al., 2007). Taken together, our data indicate that the possible 
pathomechanism of DtoV mutation involves loss and/or accumulation of mutant 
protein in pathogenic insoluble aggregates.  
 
In summary, our combined structural-functional analysis provides the first 
evidence that TK mutation is involved in human cardiomyopathy in a mechanism 
likely to involve functional crosstalk with MuRF1. Discerning between pathogenic or 
benign rare genetic variants due to unexpected variability of the human genome 
represents a challenge in the clinical setting (Mestroni and Taylor, 2013). Only very 
rarely does linkage data alone provide a definitive answer and therefore additional 
approaches should be taken. The structure-driven approach carried out in this work to 
assess the pathogenicity of DtoV could be applied to differentiate other rare benign 
genetic variants versus pathogenic mutations in DCM. 
 69"
Chapter 4  
Functional and structural consequences of I10 
domain mutation associated with arrhythmogenic 
right ventricular dysplasia "
4.1 Introduction "
Arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated and 
hypertrophic cardiomyophaties are the three major types of hereditary 
cardiomyopathies (CMs). While they all share pump failure at late disease stages, 
ARVC manifests early with life-threatening arrhythmias, making it the major cause of 
sudden cardiac death in the population aged below 25 years" (Wichter et al., 2005). 
Genetic screening for preclinical diagnosis is central to ARVC management (Sen-
Chowdhry et al., 2007). Accordingly, much emphasis has been given to identifying 
the gene mutations causing ARVC and the cellular pathways involved. Nine ARVC 
genes have been identified to date (TGFB3, RYR2, TMEM43, DSP, PKP2, DSG2, 
DSC2, JUP, TTN), of which five (DSP, PKP2, DSG2, DSC2, and JUP) encode 
proteins integral to cell-cell junctions at the intercalated disk. This finding has led to 
the belief that, mechanistically, ARVC results from a perturbed desmosomal force 
transmission. However, about 50% of ARVC affected families that undergo genetic 
screening do not show any linkage to known chromosomal loci"(Sen-Chowdhry et al., 
2007). Consequently, there is an acute need for the identification and validation of 
new causes of ARVC."
 
Recently, the importance of the titin gene (TTN) in ARVC has started to 
emerge (Taylor et al., 2011). In a recent study of 38 ARVC affected families, a 
T2850I5 TTN allele demonstrated complete co-segregation with the ARVC phenotype. 
Data suggested that the T2580I mutation causes destabilization of the titin 
immunoglobulin domain I10, to where it maps, causing augmented vulnerability of 
the titin protein to proteolysis (Taylor et al., 2011; Anderson et al., 2013,). Taylor et 
al. showed that the HSQC spectrum of the mutated I10 domain (I10T2580I) is a """"""""""""""""""""""""""""""""""""""""""""""""""""""""
5 If otherwise not indicated, titin residues are numbered according to the reference sequence protein 
entry NP_003310 
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composite of two sets of signals: a main set of well dispersed signals similar to those 
present in the WT protein and a second set with a reduced chemical shift dispersion, 
indicative of a poorly folded state. NMR findings were in good agreement with 
chemical denaturation experiments that exploited the native fluorescence of the single 
tryptophan residue in the hydrophobic core of I10. In hydrophobic environment Trp 
has a high quantum yield, which is reduced by exposure to a hydrophilic environment 
upon denaturation. Unfolding experiments revealed a diminished intrinsic 
fluorescence of I10T2580I, with little fluoresence change upon denaturation. Taken 
together, the investigations by Taylor et al. led to the conclusion that, at least, a 
fraction of I10T2580I is unfolded in in vitro samples. Anderson et al. studied the kinetic 
and mechanical stability of I10 and I10T2580I using single molecule force spectroscopy. 
They showed that the mutation decreases the force required for mechanical unfolding 
and increases the rate of unfolding by 4-fold, concurring with Taylor et al. in their 
conclusions of the overall pathomechanism of the T2580I mutation.  
 
Despite these available studies, little understanding exists to date of the 
molecular alterations induced by this mutation and its implications in vivo. Thus, in 
this work, the disease mechanism of T2850I in ARVC is investigated by applying 
structural analysis of wild-type and mutated forms of the protein as well as 
transfection studies in vivo. Insights into T2850I mutation could not be inferred from 
the current structural data on titin’s I-band. Firstly, the T2850I mutation is located in 
the proximal, constitutive I-band section of titin (Figure 4.1). Based on a key set of 
structural features within the domains and their linkers (Marino et al., 2005) Ig 
domains from this region belong to so called “N-variable” type, characterized by the 
short BC and FG loops, reduced number or absence of prolines at the N-terminal A 
strand and high sequence variability. However, all known structures of Ig-tandems 
from titin represent the “N-conserved” type. Characteristic features of this domain 
type: longer FG β-hairpins and prevalence of a PP motif at the N-terminal A strand 
orchestrate the interdomain orientation as crystal structures revealed (von Castelmur 
et al., 2008). Therefore reliable estimations could not be made for this I-band region 
based on published crystal structures. Taken together structure of I9-I11 would be 
needed for reliable estimation of T2850I mutational effects. "
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Figure 4.1 Domain organization of cardiac titin’s I-band region.  
Domains are as follows: Ig domains are in red; unique sequences in blue; Fn3 
domains in white, PEVK region in yellow. The PEVK spring region is flanked on 
either side by Ig tandems (termed “proximal” and “distal” according to their distance 
to the Z-disc). The I10 domain affected in ARVC is highlighted in pale green; boxed 
regions indicate borders of crystallized titin fragments Z1Z2 (Marino et al., 2006), I1 
(Mayans et al., 2001) I9-I11, I65-I70 (von Castelmur et al., 2008), I91 citation 
(Stacklies et al., 2009).  
 
 
 
 
4.2 Materials and Methods ""
4.2.1 Cloning "
Titin gene fragments encoding I9-I11 (residues 2749-3009 of the titin 
reference sequence NP_003310) and I10 (residues 2835-2895) were PCR amplified 
from a randomly primed cDNA library of human skeletal muscle (Table 4.1). Genes 
were then used as a source of wild-type I7-I13 fragments (residues 2560-3189), and 
the latter as source of I9-I11 and I10 coding fragments. For protein expression, 
encoding fragments were inserted into the pETM11 vector (Bogomolovas et al., 2009)"
through NcoI/Acc65I restriction sites. All constructs carried an N-terminal His6-tag 
and a TEV protease cleavage site. Upon tag removal, the GAM tripeptide remained at 
the N-terminus of recombinant proteins after the tag removal. A valine residue was 
inserted into the C-terminus of β-strand G in domain I11 to facilitate crystallization of 
I9-I11.
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Table 4.1 PCR primers used in the cloning of wild-type and mutant titin I-band 
fragments. 
Non-complementary nucleotides: restriction sites, stuffer sequence and mutation site 
are in capital letters. ""Construct" Primers""I9CI11WT" F. primer: GATC CCATG  gttaaaatcattaaaaaaccgaaagatgtgaccg R. primer: GATC GGTACC ctactaaacatacagggttgcggtgctggttgc 
I9CI11TtoI" F. primer: GATC CCATG  gttaaaatcattaaaaaaccgaaagatgtgaccg R. primer: GATC GGTACC ctactaaacatacagggttgcggtgctggttgc F. mut. primer: aaaaccatgaaaaatattgaagtgccggaaaTtaaaaccgccagctttgaatg cgaagtgagc 
R. mut. primer: 
gctcacttcgcattcaaagctggcggttttaAtttccggcacttcaatattttt catggtttt I10WT" F. primer: GATC CCATG gaaaccctgcatattaccaaaaccatgaaaaatattgaagtgccggaaac taaaaccgcc R. primer: GATC GGTACC 
ttattaggtaacggtcagggttgcgctaacctgatcattaccgcaaac aaaggtata 
I10TtoI" F. primer: GATC CCATG gaaaccctgcatattaccaaaaccatgaaaaatattgaagtgccgga aaTtaaaaccgcc R. primer: GATC GGTACC 
ttattaggtaacggtcagggttgcgctaacctgatcattaccgcaaac 
Aaaggtata 
 
 
4.2.2 Protein expression and purification "
Proteins were expressed using BL21 E.coli cells in TB (12g/L tryptone, 24 g/L 
yeast extract, 4 mL/L glycerol, 17 mM KH2PO4, 72 mM K2HPO4) medium. Cells 
were grown at 37 °C to an OD600  = 1, induced with 0.2 mM IPTG and expression 
allowed to proceed overnight at 18 °C. Cells were harvested by centrifugation at 4 °C, 
washed with Mg2+/Ca2+ free PBS (8g/L NaCl, 0.2g/L KCl, 1.44g/L Na2HPO4, 0.24g/L 
KH2PO4), repelleted and frozen at -20 °C.  For purification, the cell pellet was 
resuspended in lysis buffer (25 mM HEPES, 250 mM NaCl, 10 mM Imidazole, 0.2% 
NP-40, 2 mM β-mercaptoethanol, pH 7.5) supplemented with EDTA-free protease 
inhibitor cocktail (Roche). After resuspension, the mixture was supplemented with 1 
mg/mL lysozyme, 50 µg/mL DNAse I and 5 mM MgSO4, sonicated and centrifuged 
at 30000 g for 30 min at 4 °C. The supernatant was loaded through 0.22 µm filter onto 
Ni2+-NTA beads (Qiagen) that had been previously equilibrated in lysis buffer. Beads 
were washed with 10 x bead volumes of lysis buffer, subsequently with lysis buffer 
without detergent and eluted in 3 x bead volumes of elution buffer (25 mM HEPES, 
250 mM NaCl, 300 mM Imidazole, 2 mM β-mercaptoethanol, pH 7.5).  Eluted 
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fractions were exchanged to TEV digestion buffer (25 mM Tris, 50 mM NaCl, 5 mM 
β-mercaptoethanol, pH 7.5) using a HiPrep 26/20 Desalting column connected to an 
Äkta prime chromatography system (both GE Healthcare Life Sciences). His6-tagged 
TEV protease was then added and the mixture incubated overnight at room 
temperature. Remaining contaminants, uncleaved products, affinity tag and protease 
were removed from the cleaved protein in a second, subtractive Ni+2-NTA 
purification in TEV digestion buffer. Obtained preparations were concentrated 
(membrane cut-off 10 and 30 kDa for I10 and I9-I11 constructs, respectively) and 
further purified on a HiLoad 16/60 Superdex 75 prep grade column in crystallization 
buffer (20 mM HEPES pH 7.3, 50 mM NaCl, 0.5 mM TCEP). The I9-I11 sample was 
concentrated to 12 mg/mL and I10 to 24 mg/mL (according to A280) and stored at 4 oC 
until further use. Purity was confirmed by SDS-PAGE. 
 
For NMR studies, I10 was produced in M9 medium with 15NH4Cl as source of 
nitrogen and 13C glucose as carbon source. Protein expression and purification was 
performed as described above for the unlabeled protein. Gel filtration was performed 
in NMR buffer (20 mM Tris pH 7, 50 mM NaCl, 0.5 mM TCEP, 0.2%NaN3). For 
NMR studies, the sample was concentrated to 2 mM. 
 
 
4.2.3 Differential scanning fluorimetry "
The melting temperatures of the I10 domain and its variants were determined 
by differential scanning fluorimetry (DSF). Measurements were performed in 
triplicate on a Mx3005P Real-Time PCR System (Stratagene). The fluorescence of 
SYPRO Orange (Invitrogen) was monitored using custom FAM (492 nm) and ROX 
(610 nm) filters for excitation and emission, respectively. Measurements were 
performed in optical 96-well plates (Applied biosystems); each well contained 25 µL 
mixture consisting of 5 µM protein, 15X SYPRO Orange in assay buffer (100 mM 
HEPES pH 8, 150 mM NaCl). Fluorescence was recorded at 1 °C/min temperature 
ramp from 25 to 95 °C. The melting profiles recorded were analysed the with 
MATLAB technical computing package using a script for the fitting of the Boltzmann 
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equation with linear pre- and post- transitional fluorescence shifts as described 
(Matulis et al., 2005)."
 
4.2.4 Crystallization and crystal structure determination of I10 "
 The crystallization screening of I10 was performed at the BZH (Biochemie-
Zentrum Heidelberg) crystallization platform using a Phoenix RE (Rigaku) nanolitre 
crystallization robot. The screening was performed in 96-well Intelliplates (Art 
Robbins Instruments) at 18 °C, using the vapour diffusion method in sitting drops 
containing 500 nL protein stock and 500 nL of mother liquor. Initial crystals appeared 
in 0.2 M CaCl2, 20% [w/v] PEG 3350 after four days. The crystals were optimized 
manually in 48-well VDX plates (Hampton Research) at 20 °C in hanging drops 
consisting of 1 µL protein solution at 24 mg/mL and 1 µL of mother liquor. Crystals 
used for X-ray diffraction grew in two conditions: [A] 0.2 M CaCl2, 30% [w/v] PEG 
3350, 0.1 M Tris pH 7.5, 3% [v/v] Isopropanol; and [B] 0.2 M CaCl2, 25% [w/v] PEG 
8000, 0.1 M Tris pH 7.5. Selected crystals were cryoprotected by soaking in mother 
liquor supplemented with 30% [v/v] glycerol before being flash frozen in liquid N2.  
 
X-ray diffraction data were collected on beamline I24 [A] and I04-1 [B] at the 
Diamond Light Source synchrotron (Didcot, Oxfordshire, UK) using a PILATUS 6M 
[A] or PILATUS 2M [B] photon counting detector (Dectris, Baden, Switzerland). 
Data processing was performed using XDS/XDSCALE (Kabsch, 2010) or SCALA 
(Evans, 2006) for [A] and [B] crystal forms, respectively. Table summarizing data 
collection and refinement is presented in the corresponding result subsection. 
 
Phasing of the crystal structure from condition [B] was done by molecular 
replacement with Phaser (McCoy, 2007) using as a search model the NMR solution 
structure of I10 obtained in this study (see below). The model was manually rebuilt in 
Coot (Emsley et al., 2010) and refined using phenix.refine (Adams et al., 2011) 
treating each Ig domain as a TLS (Translation/Libration/Screw) group. The structure 
so calculated was used as search model in molecular replacement to phase the high 
resolution X-ray diffraction data collected from crystals grown in condition [A]. 
Model refinement was as above, except that automatic model building was included 
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using ARP/wARP (Langer et al., 2008). This overall strategy for structural 
elucidation was chosen because data obtained from I10 crystal in condition B had 1 
protein copy per asymmetric unit, whereas crystal in condition A contained 16 copies 
per asymmetric unit. The success of molecular replacement depends on the quality 
and completeness of the search model, and generally becomes more difficult as the 
number of components in the asymmetric unit increases (McCoy, 2007). In addition, 
NMR structures score poorer in molecular replacement. Often NMR structure of same 
protein fails when used as a search model for molecular replacement (Chen et al., 
2000). Therefore, we first obtained the best possible crystallographic search model by 
solving the phasing of the simplest asymmetric unit (containing just 1 copy) using an 
NMR model and then used the resulting crystallographic model as a search model to 
phase the data at higher resolution but with a more complex phasing problem (16 
copies). "
4.2.5 Crystallization and crystal structure determination of I9-I11 
 
Rhys Williams and Olga Mayans, University of Liverpool carried out the 
crystal structure elucidation of I9-I11. In brief, crystals were grown at 19 °C in sitting 
drops using 96-well Intelliplates (Art Robbins Instruments) and a nano-drop liquid-
dispensing robot (Screenmaker 96+8, Innovadyne). Drops consisted of 200 nL of 
protein solution (12-16 mg/mL) and 200 nL of mother liquor. Diffraction quality 
crystals were obtained from [condition C] 0.1 M Tris HCl pH 8.5, 30 % [w/v] PEG 
4000, 0.2 M MgCl2 and [condition D] 0.1 M Bis-Tris Propane pH 8.5, 20 % [w/v] 
PEG 3350, 0.2 M sodium acetate. Selected crystals were manually excised from the 
respective clusters, mounted in litho-loops and cryoprotected by soaking in mother 
liquor supplemented with 20% [v/v] glycerol before being flash frozen in liquid N2.  
 
X-ray diffraction data were collected on beamline I02 [A] and I104 [B] at the 
Diamond Light Synchrotron Source (Didcot, Oxfordshire, UK). Data collection and 
experimental setup are summarized in table 3. Data processing was performed using 
iMosflm (Battye et al., 2011) and SCALA (Evans, 2006). Phasing was by molecular 
replacement in Phaser (McCoy et al., 2007) using other titin domains as search 
models (namely, PDB ID 3CLY and 2YZ8 with ~ 30% sequence identity). The 
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molecular replacement solution was improved by automatic model building using 
ARP/wARP (Langer et al., 2008) in warpNtrace mode with side chain docking. 
Manual model manipulation used Coot (Emsley et al., 2010). Refinement was in 
phenix.refine (Adams et al., 2011) with each Ig domain defined as a separate TLS 
group. 
 
The crystal structure of I9-I11 in condition D was solved by molecular 
replacement using the crystal structure of I9-I11 from condition A as search model. 
The position of individual Ig was adjusted by rigid body refinement in phenix.refine 
(Adams et al., 2011). The model was further manually built using Coot (Emsley et al., 
2010) and refined in phenix.refine (Adams et al., 2011) treating each Ig domain as an 
individual TLS group.  ""
4.2.6 NMR studies of wild-type and mutant I10 "
This work was in collaboration with Dr. Bernd Simon at EMBL, Heidelberg. 
NMR spectra were acquired at 22 °C on Bruker DRX500, Avance III 600 and Avance 
III 700 spectrometers. Proton chemical shifts were referenced to the internal water 
signal and corrected for temperature, salt and pH, whereas heteronuclear resonances 
were indirectly referenced based on gyromagnetic ratios. All spectra were processed 
with nmrpipe and analyzed with nmrview (Johnson, 2004). Sequential backbone NH, 
N, CO, Cα and Cβ resonances were assigned from the following 3D experiments: 
HNCO, HNCA, HNCACB, CACB(CO)NH. For sidechain assignment the following 
experiments were performed: HBHA(CBCACO)NH, H(CCCO)NH-TOCSY, 
(H)C(CCO)NH-TOCSY and H(C)CH-TOCSY. Distance constraints for structure 
calculation were obtained from a simultaneous 3D 15N/13C -edited [1H, 1H]-NOESY 
(H2O) spectrum with a mixing time of 120ms. NH hydrogen bonds were determined 
by acquiring a1H-15N HSQC spectrum after dissolving lyophilised protein in D2O. 15N 
T1, T2 and heteronuclear NOE data were acquired with an interleaved data 
acquisition scheme at 500 MHz. S2 Lipari-Szabo model-free order parameter values 
where calculated with Tensor (Dosset et al., 2000).  
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Structures were calculated in Aria1.2 (Bardiaux et al., 2008) using modifed 
annealing protocols. Dihedral angle restrains were derived from the program 
TALOS+ and NOE connectivities were assigned manually and further calibrated in 8 
iterations, calculating 20 structures in first seven and 100 structures in last iteration. 
NOE restraints were used with a soft square-well potential, using an energy constant 
of 50 kcal mol−1 Å−2; dihedral angle restrains were applied with energy constants of 
200 kcal mol−1 rad−2. The bounds for hydrogen bond restrains were 1.8–2.3 Å for HN–
O distances and 2.8–3.3 Å for N–O distances. The final ensemble of structures was 
refined in an explicit water shell and the statistics of the 10 lowest energy structures 
was analyzed. 
 
4.2.7 Transgenic muscle "
The work here described was carried out in collaboration with Muzamil Majid 
Khan at University of Applied Sciences Mannheim. All animal experiments with 
wild-type C57BL/6 mice were approved by German authorities and the local 
committee (Regierungspräsidium Karlsruhe). For in vivo visualisation WT and 
mutant I7-I13 fragments were cloned into pEGFP-C1 vector, resulting in N-terminal 
fusion with EGFP. Transfection of GFP tagged I-band titin fragments into tibialis 
anterior muscles was done as previously described (Dona et al., 2003, Roder et al., 
2010). Mice were anesthetized with an intraperitoneal injection of Rompun (Bayer 
Pharma; active substance ketamine; 5mg/kg) plus Zoletil 100 (Vibrac Laboratories, 
active substances tiletamine and zolazepam; 30mg/kg). After hair removal, the skin 
and fascia overlying the tibialis anterior were incised. One electrode plate was 
inserted underneath the muscle, 10 µg of expression plasmid were injected into the 
tibialis anterior muscle and a second electrode plate was placed above the muscle. 
Five 25 V and 20 ms long electric pulses were applied (ECM 830; BTX Genetronics). 
The electrodes were removed, and the wound was closed. Ten days later, mice were 
euthanized by cervical dislocation and transfected muscle sections were 
counterstained with Texas Red®-X Phalloidin and visualized under a laser scanning 
confocal microscope or GFP expression was detected using Western Blot with anti 
GFP (abcam ab290) antibody as described (Moriscot et al., 2010).!
!
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"
4.2.8 Biomechanical measurements on cardiac myocytes 
 
This work was carried out in collaboration with Emmy Manders at VU 
University Medical Center, the Netherlands. The donor heart sample was obtained 
after informed consent and with approval of the local ethical committee, conforming 
to the principles outlined in the Declaration of Helsinki. The sample was immediately 
frozen and stored in liquid nitrogen. Cardiomyocytes were mechanically isolated from 
a left ventricular donor heart to study sarcomeric function as described previously 
(Kooij et al., 2010, van der Velden et al., 2003, van Dijk et al., 2012). Briefly, tissue 
was thawed in relaxing solution and cardiomyocyte membranes were permeabilized 
with 0.5% Triton X-100. A single cell was attached to a length motor and a force 
transducer and sarcomere length was set at 2.2 µm. Total force generating capacity 
(Ftot) was determined by transferring the cardiomyocyte to activating solution 
(calcium concentration [Ca2+]  of 31.6 µmol/L (Fabiato and Fabiato, 1978). When the 
steady force was reached, the cell was shortened to 70% of its original length, 
followed by a quick re-stretch to its original length. The rate of force redevelopment 
(κtr) was determined by fitting a single exponential through the force redevelopment 
curve (Sieck and Prakash, 1997, Brenner and Eisenberg, 1986). Passive force (Fpas) 
was determined by shortening the cell to 70% of its original length in relaxing 
solution. Active force (Fmax) was calculated by subtracting Fpas from Ftot. All 
experiments were performed at 15 °C. To determine tension, force was normalized to 
the cross sectional area of the cell. 
 
The calcium sensitivity of force was determined by placing the cell in 
solutions with incremental Ca2+ concentrations. Forces at submaximal Ca2+ 
concentrations were normalized to maximal force obtained at a Ca2+ concentration of 
31.6 µmol/L. The pCa50, i.e. the Ca2+ concentrations at which 50% of the maximal 
force is reached, was calculated by fitting a modified Hill equation through the data 
points.  Subsequently, the cell was incubated for 30 minutes with either the WT or the 
mutant fragment (concentration of 10 mg/ml in relaxing solution). After these, the 
measurements of maximal tension, passive tension, κtr, and calcium sensitivity were 
repeated. 
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4.3 Results ""
4.3.1 Expression and purification of I-band titin Ig-tandems "
Early in this work, we identified a flaw in the I10 construct design used in 
previous studies (Taylor et al., 2011; Anderson et al., 2013). Those reports used an N-
terminally truncated form of the I10 domain that missed β-strand A. It is known that 
this secondary structure element is structurally important for the Ig folds of titin 
(Pfuhl et al., 1997). Thus, we anticipated that the misconstructed I10 variants might 
have led to unreliable results. The I10 construct used in this study was N-terminally 
extended by 6 amino acids with respect to that in Taylor et al. to include the complete 
structural N-terminus of the fold (Figure. 4.2). 
 
 
Figure 4.2 Phasing of I10 domain constructs. Alignment of N-termini sequences of 
I10 domain constructs used in Taylor et al., and current work. Secondary structure 
elements are indicated according crystal structure (see below). The subsequent 
elucidation of the I10 crystal structure revealed that the domain N-terminus is 
formally defined by residue L6 in the sequence below.  
 
 
 
 
 
Recombinant immunoglobulin domain tandems from human I-band titin, both 
native and isotope labelled, were successfully over-produced in E.coli cultures. 
Protein samples were obtained in high yield (~20 mg/L medium) and at high purity 
suitable for structural studies (Figure 4.3). Gel filtration profiles for I10 (Figure 
4.3A) and I9-I11 (Figure 4.3B) indicated that the resulting samples were well-folded, 
monomeric protein preparations (as indicated by elution volumes).  
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Figure 4.3 Purification of human I-band titin Ig-tandems.  
Gel filtration chromatogram and associated SDS-PAGE of A: I9-I11WT and B: I10WT. 
 
 
 
4.3.2 DSF studies of I10 
 
Global stability of I10 domains was measured using DSF. This technique 
allows determination of melting temperature leading to the externalization of  the 
hydrophobic core marking the domain unfolding. Therefore this method was applied 
only for single domain construct I10.Both wild-type and mutant I10 gave sharp, 
directly interpretable single transition melting profiles, however mutation 
significantly reduced the melting temperature by 10.9 °C (Figure 4.4A).  
 
These findings indicate that I10 fold can well accommodate the mutation 
although at the cost of a weakened hydrophobic core. It is noteworthy that robustness 
of titin’s Ig domains might be a general feature as is was shown that the Z1 domain 
can accommodate extensive FLAG tag insertion into the CD loop (Bruning et al., 
2012).  As obtained results does not align well with the extensive domain 
destabilization reported in pervious studies (Taylor et al., 2012; Anderson et al., 2013) 
the effect of improved domain borders was evaluated. Novel design of domain 
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boarders increased the melting temperatures of both: wild-type by 10.1 °C and mutant 
by 14.2 °C (Figure 4.4B). It was noteworthy that mutational effect was larger (Tmwt-
Tmmutant =14.2 °C) between constructs used in Taylor et al., than using optimally 
designed constructs (Tmwt-Tmmutant =10.9 °C). 
 
Taken together, DSF data suggest that suboptimal design of domain boarders 
in Taylor et al. might have contributed to overestimation of  the mutational effect on 
domain stability and, thereby, the contribution of molecular instability in the ARVC 
pathology. "
Figure 4.4 DSF analysis of I10 domain stability. A. Melting curves of wild-type 
and mutant I10 proteins. T2850I exchange reduces melting temperature of I10 domain 
by 11 º C, however still remaining far above the physiological temperature range. B. 
Differences in melting temperatures of I10 domain constructs used in Taylor et al., 
and this study. Note the significant stabilization of protein constructs upon proper 
design of domain borders.  
 "
"""
4.3.3 Crystal structure of I10WT""
Previous studies on the T2850I mutation (Anderson et al., 2013, Bogomolovas 
et al., 2009) provided only a phenomenological description of mutational effects on 
protein stability, but lacked molecular insights. Therefore, here the atomic structure of 
I10 was elucidated using X-ray crystallography. Wild-type and mutant I10 were 
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assayed in crystallization, but only the wild-type variant led to crystal formation 
(Figure 4.5). 
 
 
Figure 4.5: Crystals of I10WT grown in 0.2 M CaCl2, 20% [w/v] PEG 3350 
 
 
 
  The manual optimization of the initial crystallization hit resulted in crystals of 
high diffraction quality and led to the recording of high resolution data (1.74 Å 
resolution) for I10WT in space group P212121 (condition B, Table 4.2). This crystal 
form was initially intractable by molecular replacement, because of the numerous 
protein copies in the asymmetric unit (14-16 copies estimated based on the calculated 
Matthews coefficient; Ref). Finally, this crystal form was resolved by molecular 
replacement using the crystal structure of I10 obtained from poorer quality crystals 
(2.0 Å resolution) in space group P1, but containing a single protein copy per 
asymmetric unit (Table 4.2).  
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Table 4.2 X ray data and model refinement statistics for I10WT 
 
 
 I10WT (A) I10WT (B) 
Space group P41 P212121 
Cell dimensions:   
a, b, c (Å) 
a, b, g  (°) 
31.2, 31.2, 93.9 
90, 90, 90 
74.6, 136.2, 140.1 
90, 90, 90 
Solvent content (%) 51 46 
Matthews coefficient (Å3/Da) 2.49 2.27 
Copies in ASU 1 16 
X-ray data   
X-ray source DIAMOND I24 DIAMOND I04-1 
Detector PILATUS 6M PILATUS 2M 
Wavelength (Å) 
 
 
0.9464 0.9173 
Detector-crystal distance (mm) 502 222 
Resolution (Å) 26.00-2.00 (2.071-2.00) 
29.65-1.738 
(1.80-1.738) 
Unique reflections 5665 (560) 145378 (13857) 
Rsym (I) (%) 13.9 (34.13) 9.6 (71.4) 
Multiplicity 2.2 (1.9) 7.5 (7.1) 
Completeness, % 93.2 (91.95) 98.77 (95.19) 
I/σ (I) 4.96 (2.38) 15.38 (2.77) 
Refinement   
No. of reflections 
Working/test set 5215/449 143915/1455 
Protein atoms/solvent molecules 696/123 11199/1625 
Rfactor/Rfree, % 17.53/22.99 17.45/20.49 
RMSD bond length, Å 0.007 0.007 
RMSD bond angle, ° 1.092 1.16 
 
 
The following structural details of I10WT will be discussed on the basis of the 
P212121 crystal form, elucidated at the highest resolution of 1.74 Å (Figure 4.6). 
Structural elucidation demonstrated that this crystal form contains 16 protein copies in 
the asymmetric unit. The self-rotation function calculated with POLARFN (CCP4) 
strongly implied two two-fold non-crystallographic axes: first orthogonal to the 
crystal b axis and forming an approximately 45° angle with the c axis (Fig. 4.6A), that 
can be directly recognized in the asymmetric unit (Figure 4.6B). Asymmetric unit 
consists of 4 square pyramid shaped I10 tetramers forming a hexahedron-like 
structure.  
 
 84"
Figure 4.6 Non crystallographic symmetry in I10 crystal. A. Self-rotation function 
calculated with POLARFN (CCP4) in stereographic projection at κ=180°. Peaks 
arising from twofold symmetry axes are indicated in red (crystallographic) and green 
(noncrystallographic). B. Asymmetric unit of I10WT crystal. Four square pyramid-like 
tetramers of I10 forming the unit are highlighted in different colours. 
 
 
 
I10 exhibits an immunoglobulin I-type fold, comprising nine b-strands 
(A,A’,B,C,C’,D,E,F,G) organized in two b-sheets (A,B,E,D and A',G,F,C,C’) that 
pack against each other in an antiparallel fashion. The affected threonine residue is 
located in a β-turn (residues P2848-K2851) connecting b-strands A’ and B (Figure 
4.7A). Noteworthy, identical loop conformation was observed in all protein copies 
obtained from two different crystallization conditions. According to its dihedral 
angles, this turn is classified as type II (Hutchinson and Thornton, 1994). This type of 
turns is sometimes called the “glycine” turn (Richardson and Richardson, 1989) as the 
residue i+2 adopts a left handed 310 helix conformation (ideal φ/ψ angles +90°/0°) 
that is sterically well tolerated only by glycine, which lacks a side chain.  
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Figure 4.7 Crystal structure of I10. A. Overall representation of I10WT β-sheets 
A’FCC’G and the ABED are coloured in red and blue respectively. Position of the 
T2850 mutation in the A’B b-turn is indicated by a purple sphere. B. Backbone 
representation of type II β-turn in A’B loop. Residues are numbered according protein 
sequence and β-turn naming conventions. Note the short hydrogen bond (16 kJ/mol 
according YASARA prediction) between carbonyl of i+1 and sidechain of T2850 
residue. Observed dihedral angles and ideal values of type II β-turn are given in table 
below. C. Hydrogen bonding stabilizing A’B loop. D. Ramachandran plot with T2850 
residue in high-energy region. F. Distribution of i+2 residues in A’B β-turns of 
proximal constitutively expressed titin I-band region. Note that most of the domains 
have side chain containing polar residues, whereas glycine is found only in 
approximately ¼ of the domains. 
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The sidechain Cβ atom of i+2 residue would sterically clash with the carbonyl 
group of preceding i+1 residue. Thus about 76% of this type of turns has glycine and 
only 0.7% threonine in i+2 position (Hutchinson and Thornton, 1994). However, in 
I10 such an “inconvenient” conformation is stabilized through two hydrogen bonds 
(Figure 4.7C). T2850 adopts a pseudoproline conformation by forming a hydrogen 
bond between its side chain hydroxyl and the carbonyl of the previous residue, E2849. 
The backbone position of T2850 is further stabilized through a hydrogen bond 
between the amide group of T2850 and the side chain hydroxyl of T2897 in EF loop. 
As a result, threonine in this position adopts a high-energy conformation within the 
generously allowed αL Ramachandran region.  Speculatively, such atypical 
stabilization of type II β-turns between A’ and B strands might be universal for the 
proximal constitutively expressed titin I-band region, as mostly polar residues are 
found in i+2 position (Figure 4.7E). 
 
In brief, the crystal structure of I10WT revealed that mutation affected residue 
T2850 resides in A’B loop, where it adopts atypical high-energy conformation that is 
stabilized through hydrogen bonding. Therefore T2850I mutation might have a strong 
destabilizing effect on I10 domain, by disrupting the predicted hydrogen bond 
between T2850 and E2849. ""
4.3.4 Crystal structure of I9-I11 "
The crystal structure of I10 revealed that the sidechain of T2850 is surface 
exposed (0.034 burial index as calculated with FoldX (Van Durme et al., 2011). 
Therefore, it could be involved in interactions with the preceding Ig domain and its 
mutation could lead to the destabilization of Ig-Ig interfaces. In order to address this 
question, the crystal structure of I10 flanked by its neighbouring Ig domains was 
elucidated to 1.53 Å resolution. Both wild-type and mutant constructs underwent 
crystallization screening, but only the wild-type yielded crystals. Rhys Williams and 
Olga Mayans, University of Liverpool carried out the crystal structure elucidation of 
I9-I11. 
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Figure 4.8 Appearance of initial I9-I11WT crystallization hit in situ A. Crystals in 
condition A (0.1 M Tris HCl pH 8.5, 30 % [w/v] PEG 4000, 0.2 M MgCl2); space 
group P1 B. Crystals in condition B (20 % [w/v] PEG 3350, 0.2 M sodium acetate); 
space group P212121. 
 
 
 
Two independent crystal structures of I9-I11WT were solved during the course of this 
work (Table 4.3; Figure 4.8). The crystal structure obtained from condition B was 
chosen as reference in this study as it has the highest resolution of 1.53 Å. 
 
Table 4.3: X-ray data and model refinement statistics for I9-I11 
 I9-I11 (A) I9-I11 (B) 
Space group P1 P212121 
Cell dimensions:   
a, b, c (Å) 
a, b, g  (°) 
37.7, 42.4, 83.5 
85.2, 79.8, 87.0 
42.3, 65.8, 108.4 
90, 90, 90 
Solvent content (%) 44 52 
Matthews coefficient (Å3/Da) 2.17 2.52 
Copies in ASU 2 1 
X-ray data   
X-ray source DIAMOND I02 DIAMOND I04 
Detector PILATUS 6M PILATUS 6M-F 
Wavelength (Å) 0.9795 0.9795 
Detector-crystal distance (mm) 347 285 
Resolution (Å) 19.427-1.906 (1950-1.906) 41.83-1.53 (1.610-1.530) 
Unique reflections 38254 (6392) 45488 (6392) 
Rsym (I) (%) 7.6 (64.5) 5.8 (41.4) 
Multiplicity 3.5 (3.4) 5.5 (5.1) 
Completeness, % 96.61 (86.2) 97.5 (95.9) 
I/σ (I) 11.3 (1.8) 12.6 (3.8) 
Refinement   
No. of reflections 
Working/test set 38230/1151 45171/2687 
Protein atoms/solvent molecules 4089/264 2131/543 
Rfactor/Rfree, % 19.28/22.83 16.15/19.65 
RMSD bond length, Å 0.08 0.006 
RMSD bond angle, ° 1.119 1.094 
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Figure 4.9 Crystal structures of I9-I11 A. Crystal structure solved from condition 
A, with two copies in asymmetric unit. The content of the asymmetric unit is shown. 
B. Crystal structure from crystallisation condition B with a single copy in asymmetric 
unit. This crystal structure is used as reference for the further discussion. 
 
 
I9-I11 adopts an extended conformation (Figure 4.9) observed in other known 
titin Ig-tandems (Marino et al., 2006, Muller et al., 2007, von Castelmur et al., 2008, 
Mrosek et al., 2007). Features of Ig-Ig interfaces in I9-I11 orchestrate overall domain 
arrangement that differs from the known titin Ig-domains. A Short linker connecting 
the I9-I11 fragment was compared to all other of titin’s Ig-tandems with similar 
interdomain connectors (Figure 4.10). In this work linkers were defined as regions 
with no secondary structure (coil) between G stand of preceding and A strand of 
following Ig domain, as determined with YASARA secondary structure assignment 
module. To start with, the crystal structure of I9-I11 revealed that interconnected 
domains do not adopt the “up-down” domain arrangement seen in other Ig-tandems 
from differentially expressed portion of titin I-band (von Castelmur et al., 2008) or A-
band (Muller et al., 2007, Mrosek et al., 2007) (Figure 4.10). Indeed I9-I11 has a 
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smallest domain torsion angles ranging from 45° to 68°, whereas the angle between 
other domains ranges from 80 to 144 degrees. "
Figure 4.10 Interdomain characteristics of titin Ig-Ig tandems. Upper section All 
known structures of titin Ig- tandems connected with short linkers were compared. 
The linker was considered random coil region (based on YASARA secondary 
structure assignment algorithm) between G and A’ strands of subsequent Ig domains. 
Domain torsion angle was estimated between matched regions of CD loops. Tilt angle 
calculated between the largest axes of inertia. Lower section. Structures used for the 
comparison. Corresponding β-sheets are in red and blue. """
"
 
In contrast to all described Ig-tandems, I9-I11 consists of N-variable type 
domains, defined by the shortened BC and FG elements (Marino et al., 2005) (Figure 
4.11). In the context of the titin chain, this would allow extended Ig-Ig interactions, as 
in Ig tandems from alternatively spliced region of titin’s I-band these motifs are 
orchestrating “up-down” intradomain arrangement (von Castelmur et al., 2008). Thus, 
domains in the I9-I11 tandem can adopt small domain torsion angles and form 
extensive interfaces.  
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Figure 4.11 Superimposition of N-variable and N-conserved Ig domains from 
titin I-band.  N-variable domains (I9-I11, I91) are in red N-conserved (I1, I65-I70) 
are in semitransparent gray. Note the short BC and FG loops of N-variable domains 
"
Mutation affected T2850 is buried (Burial of side chain 0.79, burial of main 
chain 0.82 calculated with FoldX (Van Durme et al., 2011)) within the extended I10-
I11 interface. I10-I11 interaction is mediated by four potential hydrogen bonds, 
mainly from the A’B loop of I10 and the BC loop of I11 (Figure 4.12B). In Ig-
tandem context T2850 residue preserves intradomain hydrogen bonds (with T2897 
and E2849) observed in I10 crystal structure and in addition is hydrogen bonded with 
S2952 from BC loop of I11 domain. In contrast to the extensive I10-I11 hydrogen 
bond network, two hydrogen bonds mediate I9-I10 interface and only E2834-H2861 
has non-local nature, connecting G strand of I9 and BC loop of I10 (Table 4.4; 
Figure 4.12CB).  
 Although domain interfaces in I9-I11 differ in hydrogen bonding patterns, 
both are mediated through conserved hydrophobic interactions. i residues (L2761 and 
P2848 for I9 and I10, respectively) of β-turn in AB loops form hydrophobic 
interactions with the residue in BC (H2861 and Y2948 for I9 and I10, respectively) 
loop of next Ig domain (Figure 4.12BC). Taken together T2850 is involved in both: 
intra- and interdomain organization of titin filament.  
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Figure 4.12 Crystal structure of I9-I11WT A. Overall representation of I9-I11WT 
crystal structure from the proximal Ig tandem segment in cartoon representation. I9-
I11 consists of three connected immunoglobulin domains. Two β-sheets (consisting of 
A’FCC’G and ABED strands) forming the Ig-fold are in red and blue, respectively. 
The T2850I mutation is represented as a purple sphere. B. I9-I10 interface. L2758 and 
H2861 are forming the hydrophobic interaction. C. I10-I11 interface. Y2948 and 
P2848 involved in hydrophobic interaction are represented in thin lines.   ""
"
Table 4.4 Inter- and intradomain contacts in I9-I11  ""
 "" "
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I9-I10 and I10-I11 interfaces differ in their interaction areas and hydrogen-
bonding pattern but retain the same hydrophobic and electrostatic interaction 
blueprints. Speculatively, corresponding hydrophobic interactions between the i 
residue of the A’B turn and the aromatic or aliphatic portion of a sidechain in the 
corresponding BC loop position (Figure 4.13AB) might be common for the 
constitutively expressed regions of titin’s I-band. In alternatively spliced region of 
titin’s I-band glycine is found in the vast majority of the domains (see Appendix 3 for 
the alignment) and the inter-residue distance is outside the hydrophobic interaction 
range (Figure 4.13C). 
 
Figure 4.13 Conserved hydrophobic in constitutively expressed region of titin’s I-
band.  A. Conserved pattern of domain linking hydrophobic interactions. i residue 
(red) in A’B turn interacts with aromatic residue (green) in BC loop of proceeding 
domain. B. Structural alignment of known titin’s I-band Ig domains with indicated 
possible interacting residues. Note that glycine is found in corresponding BC loop 
position in alternatively spliced titin’s I band Ig tandems. *,†, ‡ alignment based on I9-
I11WT, PDB ID 1G1C, 3B43, respectively; otherwise on primary sequence. C. 
Summary of predicted interaction pairs. Residues are numbered according the PDB 
coordinate files. Hydrophobic interactions predicted using YASARA software. In 
parentheses relative strength (arbitrary units) of interaction is given.  
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Electrostatic potential maps of single domains in I9-I11 tandem revealed a 
conserved pattern: negative C-terminal regions of the preceding Ig domain interact 
with the positively charged N-terminus of following domain. In the middle of the 
negative cluster a conserved glutamate resides located at the position i+1 in the A’B 
β-hairpin (Figure 4.14).  Such electrostatic patterns of domain stabilization might be 
universal for the constitutively expressed Ig tandems in I-band of titin, as high 
conservation of the described glutamate implies (see Appendix 3 for the alignment) 
Thus, taken together interdomain arrangement in I9-I11 is mediated through 
hydrophobic and electrostatic interactions that might be representative for the 
constitutively expressed regions of titin’s I-band in general. 
 
Figure 4.14 Electrostatic interdomain interactions in I9-I11. Electrostatic potential 
in vacuuo was calculated using the particle mesh Ewald approach in AMBER03 force 
field with YASARA for single Ig domains. The range and colour coding of the 
potential is +200.0 kJ/mol (blue) to -200 kJ/mol (red). Potential mapped to I9-
I11structure is presented above and negative clusters of individual domains are shown 
below. Arrows indicate position of conserved glutamate in i+1 position in A’B β-
hairpin. 
 
 
Exchange to the larger hydrophobic sidechain of isoleucine was predicted to 
have strong destabilizing effect (ΔΔG = 6.45 kcal/mol as calculated with FoldX (Van 
Durme et al., 2011)) within the I9-I11 context. This effect could be attributed to the 
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loss of hydrogen bond between the side-chain hydroxyl of T2850 and backbone 
amide of S2952. Taken together I9-I11 structure implies that T2850I exchange would 
not be tolerated and might perturb interdomain organization. 
 
4.3.5 NMR studies of I10 
 
Attempts to crystallize the T2850I mutant version of I10 or I9-I11 failed, 
therefore the mutational effect was characterized using NMR on I10. HSQC spectra 
of both wild-type and mutant I10 domain show sharp, well-dispersed peaks 
characteristic of folded proteins (Figure 4.15). However, a fraction of amide 
resonances was perturbed by the T2850I mutation. Chemical shift perturbations were 
quantified using a weighted average chemical shift difference (Nordstrand et al., 
2000) and regarded as large (0.03< ΔδAV< 0.15 ppm) or extensive (ΔδAV> 0.15 ppm). 
In the 91 residue-long I10 construct, 4 residues underwent extensive, and 21 residues 
large chemical shift perturbations. When mapped on the crystal structure of I10, the 
affected residues clustered around the mutation site primarily in the A’B and EF loop 
regions (Figure 4.16A). The perturbed residues furthest from the mutation site 
localized in the CD loop. It is noteworthy that the backbone amide in mutation site 
underwent a comparably small perturbation of only 0.06 ppm. ""
In order to address the effect of the mutation on protein dynamics, the S2 
model-free order parameter was calculated (Figure 4.16B). This parameter is a 
measure of local rigidity, where a rigid residue would acquire a value of 1 and a 
flexible residue would be 0. Comparison of wild-type and mutant I10 dynamics in 
terms of S2 indicated that the mutant exhibits increased mobility, particularly in the 
loop regions. Regions of increased local mobility match well the clusters of residues 
with the largest chemical shift perturbations. The crystal structure of I10 allowed the 
interpretation of the observed mutational effects through mapping. Chemical shift 
perturbations and increased local flexibility cluster in the BC and FC loops that are 
interconnected through hydrogen bonds mediated by T2850 (as described in Section 
4.3.4). Thus, loss of these hydrogen bonds could be in part responsible for the 
structural perturbations. To test this hypothesis, 15N-labeled I10 protein was flash 
frozen in liquid nitrogen, lyophilized, re-dissolved in D2O and its 1H-15N HSQC 
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spectrum recorded (Figure 4.17A). This experiment allowed identification of slow 
exchanging amide protons in a hydrogen-bonded state or burial inside the 
hydrophobic core. I10 and I10T2850I have nearly identical hydrogen bonding patterns 
(Figure 4.17B). However, the amide of mutant I10T2850I was no longer hydrogen-
bonded as opposed to wild-type T2850 (T20).  In consequence, a former donor of 
hydrogen bond T2897 (T67) experience extensive chemical shift perturbation of 0.47 
ppm. In a similar fashion an extensive chemical shift of E2849 (E19) could be a result 
of a lost hydrogen bond between the main-chain carboxyl group and hydroxyl group 
of T2850 (T20) side-chain. Taken together chemical shift perturbations and clusters 
of increased local mobility caused by T2850I mutation gather around the mutation 
site at the “C-terminal” loop cluster of this Ig domain caused by the altered hydrogen 
bond network. !
 
 
Figure 4.15 HSQC spectra overlay of assigned wild-type (red) and mutant 
(black) I10 domains. Most significant chemical shift perturbations are indicated. 
Residue label font size corresponds to the relative magnitude of chemical shift 
differences. 
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Figure 4.16 NMR study of mutational effects.  A. Weighted backbone amide 
chemical shift differences between wild-type and mutant I10 mapped on structure of 
I10WT. Large (0.03<ΔδAV<0.15 ppm) and extensive (ΔδAV>0.15 ppm) chemical 
shift perturbations are represented as orange and red spheres. Position of mutated 
residue is marked with white asterix.  B. S2 model free parameter for wild-type (blue) 
and mutant (red) I10. Note increased flexibility of mutant loop residues. Arrow 
indicates mutation site. Cartoon above the chart illustrates secondary structure 
elements of I10 domain. 
 
 
 
 
 
Figure 4.17 Mutational effects on hydrogen bonding A. Overlay of HSQC spectra 
before (green) and after (red) exchange to D20. Note protection from H/D exchange of 
wild-type T20, but not mutant I20 amide (arrow). B. Hydrogen-bonded amide protons 
in wild-type and mutant I10 observed by slow H > D exchange. Arrow indicates lost 
hydrogen bond upon T2850I mutation. Secondary structure elements are presented 
according the crystal I10 structure. To ease labelling in the HSQC spectra, protein 
residues are numerated with respect to the beginning of the I10 sequence as described 
in this study, so that T2850 is T20. 
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In order to reveal how observed mutational effects affect the organization of the I10 
domain solution structures were calculated (Figure 4.18A). In the NMR ensemble, β-
sheet C’ was distorted and not represented. Representative structures (calculated with 
NMRclust (Kelley et al., 1997) of wild-type and mutant I10 superimpose very well, 
giving RMSD = 1.55 Å (just marginally above the intra-ensemble variation) (Figure 
4.18B), indicating that the mutation does not affect the overall fold of I10. It is 
noteworthy that the mutated A’B loop retains the wildtype structure, whereas the 
mutant isoleucine follows the side chain of the native threonine (Figure 4.18C, 
sidechain residues).  
 
 
 99"
Figure 4.18 NMR solution structure of wild-type and mutant I10.   
A. Superimposition of WT (blue) and mutant (red) solution structure ensembles. 
T2850/I2850 are represented as sticks. B. NMR and refinement statistics for protein 
structures. C. Superimposition of representative (calculated with NMRclust) wild-
type (blue) and mutant (red) NMR structures. 
 
 
 
 "
Taken together, NMR analysis of WT and mutant I10 revealed that the 
pathogenic T2850I mutation does not largely alter the fold, but affects protein 
dynamics by increasing loop flexibility. ""
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4.3.6 Effects of T2850I on protein stability and localization in vivo"
 
To test whether the T2850I mutation led to a differential functionality in vivo, 
we assayed fragments of the titin chain in skeletal muscle. For this work, GFP-tagged 
titin fragments were introduced into skeletal muscle of live mice. The work here 
described was carried out in collaboration with Muzamil Majid Khan at University of 
Applied Sciences Mannheim. 
 
GFP tagged wild-type and mutant I7-I13 Ig-tandem fragments were 
introduced into tibialis anterior muscle of living mice via electroporation. In order to 
minimize possible tag-caused interference extended titin fragments were chosen in 
this experimental setup. The cellular fate of titin fragments in transfected muscle 
extracts was followed by Western Blot, using anti-GFP antibody. Single sharp protein 
bands corresponding to the expected molecular weight of the constructs were detected 
by blotting (Figure 4.19 left panel). No visible signs of degradation were observed for 
either the wild-type or mutant I7-I13. In summary, although the T2850I exchange has 
a destabilizing effect on the isolated I10 domain in vitro, the latter does not result in 
increased degradation of mutant titin fragments expressed in muscle of live mice. !
!
Imaging of transfected muscles revealed a differential myocellular localization 
of the wild-type and mutant I7-I13 protein (Figure 4.19 middle and right panels) WT 
fragments remained mostly soluble inside the cytoplasm, with only weak signs of 
striated pattern. However, the mutant I7-I13 acquired a striated pattern. In order to 
better characterize the observed staining patterns, fixed transgenic muscle sections 
were co-stained with fluorescent phalloidin conjugate. Phalloidin binds to thin 
filament-forming F-actin. Double labelling revealed that the wild-type construct 
concentrates in areas lacking F-actin (i.e. A-band), whereas the mutant fragment 
colocalized with phalloidin conjugate stained thin filament. Colocalization with F-
actin in “double-band” striation pattern of mutant fragment in skeletal muscle 
resembles alignment laterally to the Z-disks. Such pattern would be expected for the 
native I10 position however other structures such as terminal cisternae of the 
sarcoplasmic reticulum would result in indistingusible staining pattern (Nori et al., 
2006). The latter is of particular interest, as tsO45 mutant vesicular stomatitis virus 
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accumulates in the same pattern (Rahkila et al., 1996) when temperature is increased 
to induce its misfolding (Hammond and Helenius, 1994) and causes ER stress 
response. In similar fashion, the striated pattern of mutant I7-I13 myocellular 
localization could be the result of association with the structures of 
endoplasmic/sarcoplasic reticulum, caused by mutation-induced propensity to 
misfold. In order to test this hypothesis further studies are needed. As a primary 
experiment, differences in cellular response to the mutant and wild-type protein have 
to be compared. In summary, in vivo localization studies revealed that T2850I 
mutation alters myocellular localization but not the stability of I7-I13 titin fragments 
and further studies are needed to elucidate the cause of the observed differences.!
!
Figure 4.19 In vivo studies of I7-I11 fragments. Panel Left. Stability of I7-I11 
fragments in vivo. Western blot with anti-GFP antibody (left) and corresponding 
Coomassie stained gel of transgenic T. anterior muscles. Both, WT and mutated I7-
I13 were stably expressed for two weeks in vivo, and Western blots indicated no 
proteolytic degradation. Middle panel. Differential localization of wild-type and 
mutant I7-I13 titin fragments in muscle. WT I7-I13 GFP fusion proteins remained 
mostly diffuse in the cytoplasm, whereas T2850I mutated I7-I13 fragments targeted to 
the myofibril. Right panel. Double labelling with phalloidin revealed that mutated I7-
I13 fragments in myofibrils co-localise with phalloidin, while mutant I7-I13 matches 
the tkick filament region. "
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4.3.7 I7-I13 titin fragments affects cardiomyocyte contractility 
 
Since the in vivo localisation studies detected a colocalization of T2850I 
mutated titin fragments with thin filaments, it was speculated that mutated titin 
fragments might alter the biomechanical properties of cardiomyocytes by interference 
with the force-bearing cross-bridges. To test this hypothesis, maximal tension and 
calcium sensitivity of skinned human cardiomyocytes was determined before and 
after addition of recombinant titin fragments to the assay solution. The biomechanical 
measurements were performed by Emmy Manders at VU University Medical Center, 
the Netherlands. 
  "
I7-I13 fragments had an effect on cardiomyocyte biomechanical properties. After 
addition of recombinant protein maximal active tension was reduced and calcium 
sensitivity increased (Figure 4.20). T2850I mutated titin fragment caused a 10% 
reduction of maximal tension. WT fragments demonstrated the same characteristics 
but due to higher variance and outliers the results did not reach statistical significance. 
Increased calcium sensitivity after titin fragment addition was noted for both WT and 
mutant fragments, but more pronounced after the addition of mutant fragment (Figure 
4.20B). "
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Figure 4.20 Effect of recombinant I7-I13 fragments on the biomechanical 
properties of the cardiomyocytes. Human left ventricle cardiomyocytes were 
characterized biomechanically for active force and calcium sensitivity of force. Same 
measurements were repeated after incubation with recombinant titin fragments. A. 
Addition of mutant I7-I13 significantly decreased maximal active tension, whereas 
effect of WT protein did not reach statistical significance. Note higher data variation 
and presence of outlier in wild-type experiment. B Slight but significant increase of 
calcium sensitivity was seen for both WT and T105I fragments.  "
 
 
Obtained data does not exclude the posibility that the T2850I mutation might 
alter biomechanical cardiomyocyte properties. However additional experiments are 
required to understand/validate this phenomenon.  Firstly, only 5-6 myocytes were 
used per experimental group making this dataset extremely sensitive to outliers. 
Therefore in order to gain solid statistical conclusion experiments should be repeated 
with higher biological replicate numbers. Secondly, buffers  used for the pretreatment 
measurements and one with studied proteins originate from different batches so this 
experiment was not controlled for the buffer effects. Thus subtle changes in buffer 
compostion could have caused observed changes of biomechanical parameters. 
Finally, in order to link biomechanical alterations to pathogenesis of T2850I 
associated ARVC proper localization of recombinant titin fragments in skinned 
myofiber lattice should be confirmed.  
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Taken together, although these experiments lacking critical biological and 
technical controls preliminary data does not contradict the hypothesis that T2850I 
mutation might have an effect on the biomechanical myofibril properties.  
4.4 Discussion "
Performed work provides structural and physiological insights into T2850I 
mutation within the I10 domain alone and in context of neighbouring domains I9-I11. 
Obtained results demonstrated that the affected threonine residue adopts a high energy 
conformation, stabilized by two hydrogen bonds that are lost upon mutation, leading 
to the significant destabilization of the domain. In the context of the titin chain, the 
affected threonine was found to mediate Ig-Ig interactions. However, the weakening 
of mutant I10 observed in vitro did not translate into an increased titin chain fragment 
propensity for degradation in vivo, but rather caused differential myocellular 
targeting.  
 
Obtained results are in contrast to previous structural studies on T2850I 
mutation (Taylor et al., 2011; Anderson et al., 2013) claiming domain destabilization 
as a major pathogenetic effect. In this work mutation caused a significant drop in 
melting temperature, indicative for domain destabilization, but was compatible with 
the Ig fold as revealed by NMR analysis. This observation is coherent with the 
reported outstanding mutational robustness of the titin Ig domain (Bruning, et al 
2012). The overestimation of destabilizing effects could have been caused by 
suboptimal construct design used in previous studies on T2850I mutation. Sequence 
analysis revealed that the I10 construct was missing the A strand, which impaired 
intrinsic domain stability. Thus taken together, obtained results indicate that domain 
unfolding is unlikely factor in T2850I caused ARVC. 
 
I10 structures revealed that the sidechain of the affected threonine is directed 
outwards the Ig domain, suggesting that T2850I might have an effect on interdomain 
interactions. In order to test this hypothesis the crystal structure of I10 surrounded by 
the neighbouring I9 and I10 domains was solved. The crystal structure revealed that 
the affected threonine is located in the middle of an extensive 5-hydrogen bond 
stabilized interface between I10 and I11. Conserved hydrophobic interdomain 
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interaction was observed in I9-I11 structure.  Speculatively, T2850I exchange in the 
confined I10-I11 interface would disturb both polar and non-polar interactions. Thus, 
the disruption of the Ig-Ig interface might result in exposure of an interdomain 
hydrophobic patch. Taken together structural analysis suggested that the T2850I 
exchange effect might be composite and involve both local destabilization of I10 
domain itself and exposure hydrophobic patch at the I10-I11 interface. 
 
In order to gain insights into how proposed alterations might translate into 
physiological phenomena, the cellular fate of titin fragments was followed in skeletal 
muscle and the effect of recombinant protein on biomechanical properties of skinned 
human cardiac myocytes was measured.  GFP-tagged wild-type and mutant I7-I13 
fragments introduced into skeletal muscle of live mice show no obvious signs of 
degradation: using transgenic muscle extracts single band of expected molecular 
weight was detected using Western blot with anti-GFP antibodies. However, 
myocellular localization of titin fragments is different. While the vast majority of 
wild-type protein was diffuse, mutant protein tended to colocalize laterally to the Z-
discs. Observed phenomenon could be interpreted in several ways. Firstly, earlier data 
suggested that the proximal titin Ig tandem segment close to the Z-disk has a 
propensity to weakly interact with the thin filament (Trombitas et al., 1993, Trombitas 
and Pollack, 1993, Trombitas et al., 1997). Therefore, T2850 exchange might stabilize 
this interaction by exposing a hydrophobic patch along the titin filament, conferring a 
non-physiological stickiness of titin to the thin filament. Thus, an increase in affinity 
would be sufficient to overcome the entropic barrier and allow mutant titin fragment 
to target expected localization, whereas physiological affinity of wild-type would not 
be sufficient for the proper localization within the myofibril in the described 
experimental setup. In similar fashion, pathologically increased affinity of filamin C 
to F-actin was shown to cause distal myopathy (Duff et al., 2011). Consequently, 
more stable titin- thin filament interaction would affect myofibrillar biomechanics and 
perhaps indirectly the Frank-Starling mechanism. Preliminary results do not 
contradict the hypothesis that recombinant I7-I13 fragments might have an effect on 
biomechanical properties. It should be noted that in in vitro single myofibril 
experiment, a molar excess of mutant titin fragments was added in solution. In vivo in 
ARVC affected hearts, only a single titin hydrophobic patch will be present that is 
unlikely to inhibit numerous actomyosin crossbridges. Therefore, future studies will 
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need to test the effect of introducing the T2850I allele into transgenic mice, and if this 
leads to more stable titin – thin filament associations within the periphery of the Z-
disk, possibly in turn connected to a pathological activation of strain-sensing 
pathways at resting sarcomere lengths. On the other hand, observed mutant 
localization might be caused by the association with the structures of the sarcoplasmic 
reticulum. A Z-disc-like localization pattern does not necessary indicate association 
with the myofibril itself, because most of the cellular compartments and organelles in 
myocytes align into well-defined striations. Observed mutant I7-I13 localization 
pattern is identical to one observed for the folding defective viral probes (Kaisto and 
Metsikko, 2003, Rahkila et al., 1996), accumulating in terminal cisternae. In context 
of structural insights, this allows us to hypothesise that T2850I mutation in a cellular 
context might result in entrapment and accumulation of misfolded, degradation-
resistant mutant titin fragments in the sarcoplasmic reticulum. However, studied GFP-
tagged titin fragments do not have obvious signal peptides for ER targeting, but it was 
demonstrated that removal of misfolded cytosolic proteins require association with 
the endoplasmic reticulum (Metzger et al., 2008). In line with this hypothesis T2850I 
mutation would cause shortage of mutant titin molecules and a permanent 
endoplasmic reticulum stress response. The following could lead to heart disease as it 
was shown that titin transcript levels are reduced in dilated cardiomyophaty affected 
human hearts (Ahmad et al., 2010) and accumulation of misfolded proteins in the ER 
in transgenic mouse model causes dilated cardiomyopathy (Hamada et al., 2004). 
Thus, according this hypothesis the molecular pathomechanism of T2850I associated 
cardiomyopathy would resemble the one of ΔF508 caused cystic fibrosis, where 
mutant protein is partially retained in the endoplasmic reticulum (Kopito, 1999) 
resulting in deficiency of protein in the plasma membrane.  
 
Taken together structural analysis provided a solid basis for the future 
elucidation of T2850I caused cardiomyopathy. Based on obtained data two novel 
molecular scenarios are proposed as how to T2850I exchange might lead to heart 
disease. According the first scenario, mutation might increase titin stickiness to the 
thin filament, inhibiting numerous actomyosin crossbridges and inducing pathological 
activation of strain-sensing pathways at resting sarcomere lengths. Attenuation of 
such strain-sensing pathways would then be a rational therapeutic to combat the 
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second scenario, misfolded mutant protein accumulates in the sarcoplasmic reticulum, 
resulting in shortage of functional titin filaments and permanent ER stress. 
Speculatively, T2850I mutation carrying patients could benefit from stimulation of 
folding-machinery to counteract shortage of functional titin molecules or activation of 
autophagy in order to “clean up” the “clogged” non-functional ER.  
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6 General discussion 
 
In this work, a structure-driven approach was taken to gain insights into the 
function of the titin filament with emphasis on TK. In contrast to the scientific 
consensus, this work demonstrated that TK is a catalytically inactive molecular 
scaffold physically interconnected with the ubiquitin ligase MuRF1 signalling axis. 
Mutational perturbation of this link was found to be associated with DCM. A similar 
pattern of mutation-induced weakening of interdomain interactions was proposed as a 
pathogenetic trigger causing ARVC.   
 
Discrimination between rare benign genetic variations and pathogenic 
mutations is a complex task (Mestroni and Taylor et al., 2013), due to the 
unexpectedly large number of rare genetic variants in the human genome (Nelson et 
al., 2012, Keinan and Clark 2012). In this work, supportive validation of pathogenic 
titin mutations was attained by the structural analysis of mutation-affected titin 
structures. Although the structures of mutants were not obtained in most cases, 
analysis of wildtypes allowed us to deduce mutational effects and directed subsequent 
functional studies. Biological effects caused by the D24728V mutation were studied 
in cell culture. Chosen experimental setup has limited potential as organ- and organ 
system- level phenomena (for example, pressure, contractility) cannot be produced 
but might act as major factors in disease ethiology.  Effects of T2850I were studied in 
live animals but in skeletal instead of cardiac muscle, due to technical advantage. 
Thus, ectopic protein expression in a skeletal muscle is not sufficient to recreate the 
environment of heart and important factors might be missing in a given setup. Using 
in vivo approach differential responses to the mutant proteins were detected, however 
how the observed differences translate into the disease phenotype remains an open 
question(s) for the further studies. Taken together, this novel approach might help to 
increase confidence in discrimination of novel pathogenic titin mutations from benign 
genetic variations. 
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The structural effects of two cardiomyopathy-associated titin mutations 
studied in this work revealed shared conceptual similarities. Mutations presented in 
this work are different in the nature of amino acid substitution, localization in the 
sarcomere and protein folds affected. However, interactions between the domains 
were impaired in both cases. It is known that alteration of protein-protein binding 
affinities might lead to disease. However, the detrimental effect of altered interdomain 
interactions is a novel observation.  The results presented underscore the importance 
of studying titin within the context of neighbouring domains, as this approach would 
allow a more complete insight into the pathogenic effects of mutations.  
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Chapter 8 Appendices 
8.1 Major types of intrinsic human cardiomyopathies "
Cardiomyopathy Clinical features 
Dilated 
Gradual increase in left ventricular chamber volumes, 
wall thinning and change in geometry to more 
spherical, associated with the primary decline in 
systolic heart function. 
 
Hypertrophic 
Thickening of left ventricle, due to pathological 
hypertrophy associated with myocardial disarray (both 
myocytes and sarcomeres), cardiac fibrosis; altered 
chamber shape and biomechanical properties 
manifests in combined diastolic-systolic dysfunction, 
dynamic outflow obstruction and arrhythmias. 
 
Arrhythmogenic 
right ventricle 
Isolated thinning of right ventricle due to fibrofatty 
infiltration, causing an early conduction disturbances 
leading to the life-threatening arrhythmias 
 
Restrictive 
Rigid walls of cardiac chambers restrict the heart from 
stretching and filling blood properly. Primary severe 
diastolic dysfunction leading to the biartrial 
enlargement, elevated artrial pressure and left 
ventricle wall thickening, without chamber dilatation. 
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8.2 Appendix 1 Sequence conservation of VAIK and DFG 
motifs in TK-like kinases from vertebrates and invertebrates 
!
!
Vertebrate titins! ! ! VAIK                 DFG !
Homo_sapiens   CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Ailuropoda_melanoleuca       CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Anolis_carolinensis          CVETATKKTYLAKFVKVKGADQVLVK .... IIKIIEFGQARQL 
Bos_taurus                   CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Callithrix_jacchus           CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Canis_familiaris             CVETSSKKTYMAKFVKVKGTDQVLVK .... IIKIIEFGQARQL 
Cavia_porcellus              CVETSSKKTFMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Danio_rerio_A                CIETSSEKTYMAKFVKVKGADQALVK .... NVKIIELGQSRHL 
Danio_rerio_B                SIEISSKKTFLAKFIKVKGADRELVA .... TIKIIEMGQARLL 
Dasypus_novemcinctus         CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Dipodomys_ordii              CVETSSKKTFMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Echinops_telfairi            CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Equus_caballus               CVETSSKKTYMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Erinaceus_europaeus          CVETSSKKTYMAKFVKVKGTDQVLVK .... IIKIIEFGQARQL 
Felis_catus                  CVETSSKKTYMAKFVKVKGTDQVLVK .... SIKIIEFGQARQL 
Gadus_morhua_A               CVEIATKKTFMAKFIKVKGMDRELVL .... ELKIIEMGQARLL 
Gadus_morhua_B               CVEKSSERTYMAKFVKVRGADQAIVK .... NVKIIELGQCRHL 
Gallus_gallus                CVEAVSKKTYLAKFVKVKGADQVLVK .... VVKIVEFGQARQL 
Gasterosteus_aculeatus_A     CTEIATKKTFMAKSIKVKGTDRELVL .... TTKIIEMGQARLL 
Gorilla_gorilla              CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQAHQL  
Ictidomys_tridecemlineatus   CVETSSKKTFMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Latimeria_chalumnae          CVENTSKKTYMAKFVKVKGADQVLVK .... LVKIIELGQARQL 
Loxodonta_africana           CVETSSKKTFMAKFVKVKGTDQVLVK .... TVKIIEFGQARQL 
Macaca_mulatta               CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Macropus_eugenii             CVETSSKKTYMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Meleagris_gallopavo          CVEAVSKKTYLAKFVKVKGADQVLVK .... VVKIVEFGQARQL 
Microcebus_murinus           CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Monodelphis_domestica        CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Mus_musculus                 CVETSSKRTFMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Myotis_lucifugus             CVETSSKKTYMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Nomascus_leucogenys          CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Ochotona_princeps            CVETSSKKTFMAKFVKVKGTDQVLIK .... VIKIIEFGQARQL 
Oreochromis_niloticus        CVEISSEKTYMAKFVKVRGADQTLVK .... NVKIIELGQSRHL 
Ornithorhynchus_anatinus     CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Oryctolagus_cuniculus        CVETSSKKTFMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Oryzias_latipes_A            CTEIATKKTFMAKFIKVKGTDRELVL .... NIKIIDMGQSRLL 
Oryzias_latipes_B            CVNISSEKTYMAKFVKVRGADQAIIK .... NVKIIELGQSRHL 
Otolemur_garnettii           CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Pelodiscus_sinensis          CVETVSKKTFLAKFVKVKGADQVLVK .... IIKIIEFGQARQL 
Petromyzon_marinus           CVEISSKKTYMAKFAKVKGADQGSTK .... RVKLVEFGQARIL 
Pongo_abelii                 CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Procavia_capensis            CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Pteropus_vampyrus  CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Rattus_norvegicus            CVETSSKKTFMAKFVKVKGTDQVLVK .... IIKIIEFGQARQL 
Sarcophilus_harrisii         CVETSSKKTYMAKFVKVKGTDQVLVK .... VIKIIEFGQARQL 
Sorex_araneus                CVETSSKKTYMAKFVKVKGTDQVLVK .... LIKIIEFGQARQL 
Sus_scrofa                   CVETSSKKTYMAKFVKVKGADQVLVK .... TIKIIEFGQARQL 
Takifugu_rubripes_A          CVEIATKKTFMAKFIKVKGTDRELVL .... NIKIIEMGQARLL 
Takifugu_rubripes_B          CVDICSEKTYMAKFVKVRGADQALVK .... NVKIIELGQCRHL 
Tetraodon_nigroviridis_A     CVEIATKRTFMAKFIKVKGTDRELVL .... TIKIIEMGQARLL 
Tupaia_belangeri             CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Xenopus_tropicalis           CIENSSKKTYLAKFVKVKGADQVLVK .... TIKITEFGQARQL 
Cricetulus_griseus           CVETSSKKTFMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Mustela_putorius_furo        CVETSSKKTYMAKFVKVKGTDQVLVK .... TIKIIEFGQARQL 
Heterocephalus_glaber        CVETSSKKTFMAKFVKVKGTDQVLVK .... IIKIIEFGQARQL 
Xiphophorus_maculatus_A      CVEIATKKTFMAKFIKVKGTDRELVL .... NIKMIEMGQSRLL 
Xiphophorus_maculatus_B      CVDISSEKTYMAKFVKVRGADQAIIK .... TVKIIELGQSRHL ""
!
!
!
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Invertebrate! titin+like! kinases! (include! twitchin,! projectin! and! TTN+1!
kinases)!
!
Caenorabditis_elegans  NNFAAKFVM .... ELKLIDFGLTAHL  
Caenorhabditis_briggsae   NNFAAKFVM .... ELKLIDFGLTAHL  
Caenorhabditis_remanei   NNFAAKFVM .... ELKLIDFGLTAHL  
Ascaris_suum     NTFAAKFVN .... QLKLIDFGLAAKL  
Brugia_malayi    NTFAAKFVN .... QLKLIDFGLAAKL  
Loa_loa      NTFAAKFVN .... QLKLIDFGLAAKL   
Trichinella_spiralis  NVFAAKFVN .... VLKLIDFGLAAKL  
Tribolium_castaneum  NIFAAKFIP .... NIKLIDFGLATKL  
Pediculus_humanus  SIFAAKFIP .... NIKLIDFGLATKL  
Procambarus_clarkii    NIFAAKFIP .... NVKLIDFGLATKL  
Harpegnathos_saltator   NIFAAKFIP .... NVKLIDFGLATKL  
Mytilus_galloprovincialis RVFVAKFIN .... EVKMIDFGLATKL 
Crassostrea_gigas  RVFVAKFIN .... NVKMIDFGLATKL 
Aplysia californica  RVFVAKFIN .... SVKIIDFGLATKL 
Drosophila_willstoni  NIFAAKFIP .... SVKLIDFGLATRL  
Drosophila_pseudoobscura NIFAAKFIP .... NVKLIDFGLATRL  
Drosophila_persimilis  NIFAAKFIP .... NVKLIDFGLATRL  
Drosophila_melanogaster NIFAAKFIP .... NVKLIDFGLATRL  
Aedes_aegypti   NVFAAKFIP .... NVKLIDFGLATRL  
Anopheles_darlingi  NVFAAKFIP .... NVKLIDFGLATRL  
Anopheles_gambiae  NVFAAKFIP .... NVKLIDFGLATRL  
Culex_quinquefasciatus  NVFAAKFIP .... NVKLIDFGLATRL  
 
8.3 Appendix 3 Structure based alignment of Ig domains from 
titin I-band "NCtermini"of"Ig"domains"are"represented."i+2"residue"of"βCturn"between"A’"and"B"sheets"is"in"red."Residue"positions"forming"interdomain"hydrophobic"interaction"in"I9CI11"are"in"green"and"joined"with"bow."NonCglycine"residues"are"underlined."Conserved"glutamate"between"A’"and"B"sheets"is"in"blue."Residues"are"numbered"according"Uniprot"entry"Q8W742."Where"possible"crystal"structures"were"used"
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